[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 254
1. Barua N, Hilton DA, Mukonoweshuro W, Khalil H, Pobereskin L: Persistent CSF Rhinorrhoea, Pneumocephalus, and Recurrent Meningitis Following Misdiagnosis of Olfactory Neuroblastoma. Case Rep Med; 2010;2010

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent CSF Rhinorrhoea, Pneumocephalus, and Recurrent Meningitis Following Misdiagnosis of Olfactory Neuroblastoma.
  • Histological examination of an endonasal transethmoidal biopsy suggested a diagnosis of olfactory neuroblastoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20811561.001).
  • [ISSN] 1687-9635
  • [Journal-full-title] Case reports in medicine
  • [ISO-abbreviation] Case Rep Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2929619
  •  go-up   go-down


2. Wang CC, Chen YL, Hsu YS, Jung SM, Hao SP: Transcranial resection of olfactory neuroblastoma. Skull Base; 2005 Aug;15(3):163-71; discussion 171

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcranial resection of olfactory neuroblastoma.
  • From February 1995 to August 2004 at Chang Gung Memorial Hospital and Chang Gung University, eight patients with an olfactory neuroblastoma underwent transcranial resection alone.
  • The transcranial surgical technique consisted of a bicoronal incision, followed by a standard frontal craniotomy with or without a separated orbital bar osteotomy.
  • With thorough knowledge of the basic topographic anatomy of the anterior cranial base, transcranial resection can provide adequate surgical exposure to facilitate oncologically sound resection and to execute reliable skull base reconstruction in selected patients with an olfactory neuroblastoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Otolaryngol Allied Sci. 1999 Sep;24(5):457-61 [10542931.001]
  • [Cites] Laryngoscope. 1990 Nov;100(11):1199-201 [2233084.001]
  • [Cites] Arch Otolaryngol. 1977 Sep;103(9):514-7 [332133.001]
  • [Cites] Cancer. 1979 Sep;44(3):1087-94 [383268.001]
  • [Cites] Cancer. 1995 Jul 1;76(1):4-19 [8630875.001]
  • [Cites] Neurosurgery. 1996 Mar;38(3):471-9; discussion 479-80 [8837798.001]
  • [Cites] J Otolaryngol. 1997 Feb;26(1):1-7 [9055166.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4A):2683-706 [9252701.001]
  • [Cites] Am J Surg. 1997 Nov;174(5):565-8 [9374239.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Dec;123(12):1312-7 [9413360.001]
  • [Cites] Head Neck. 1999 Jan;21(1):12-20 [9890346.001]
  • [Cites] Laryngoscope. 1999 Jan;109(1):153-60 [9917058.001]
  • [Cites] J Formos Med Assoc. 2000 Dec;99(12):914-9 [11155744.001]
  • [Cites] Otolaryngol Head Neck Surg. 2001 Mar;124(3):292-6 [11240994.001]
  • [Cites] Am J Rhinol. 2001 Jul-Aug;15(4):271-9 [11554661.001]
  • [Cites] Laryngoscope. 2002 Sep;112(9):1691-5 [12352688.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] Laryngoscope. 2003 Mar;113(3):502-7 [12616204.001]
  • [Cites] Otolaryngol Head Neck Surg. 2003 Apr;128(4):571-5 [12707663.001]
  • [Cites] Head Neck. 1992 Nov-Dec;14(6):477-82 [1468921.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):843-9 [1495347.001]
  • [Cites] J Neurosurg. 1992 Feb;76(2):198-206 [1730948.001]
  • [Cites] Laryngoscope. 2000 Apr;110(4):635-40 [10764010.001]
  • (PMID = 16175226.001).
  • [ISSN] 1531-5010
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1214702
  •  go-up   go-down


3. Guled M, Myllykangas S, Frierson HF Jr, Mills SE, Knuutila S, Stelow EB: Array comparative genomic hybridization analysis of olfactory neuroblastoma. Mod Pathol; 2008 Jun;21(6):770-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Array comparative genomic hybridization analysis of olfactory neuroblastoma.
  • Olfactory neuroblastoma is an unusual neuroectodermal malignancy, which is thought to arise at the olfactory membrane of the sinonasal tract.
  • The aim of the current study is to identify specific DNA copy number changes in olfactory neuroblastoma.
  • Our results show that gene copy number profiles of olfactory neuroblastoma samples are complex.
  • Gains were more frequent than losses, and high-stage tumors showed more alterations than low-stage olfactory neuroblastoma.
  • In addition, our results indicate that gains in 20q and 13q may be important in the progression of this cancer, and that these regions possibly harbor genes with functional relevance in olfactory neuroblastoma.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / genetics. Nasal Cavity / pathology. Nose Neoplasms / genetics. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18408657.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Sampath P, Park MC, Huang D, Deville C, Cortez S, Chougule P: Esthesioneuroblastoma (olfactory neuroblastoma) with hemorrhage: an unusual presentation. Skull Base; 2006 Aug;16(3):169-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esthesioneuroblastoma (olfactory neuroblastoma) with hemorrhage: an unusual presentation.
  • Esthesioneuroblastoma (olfactory neuroblastoma) is an uncommon neuroectodermal tumor.
  • Patients often present with nasal obstruction, rhinorrhea, recurrent epistaxis, hyposmia, or anosmia.
  • However, we report the highly unusual case of a patient with an esthesioneuroblastoma who presented with atypical symptoms of headaches, sinus congestion, and fatigue before acutely losing consciousness.
  • This is the first reported case of an esthesioneuroblastoma presenting with hemorrhage and rapidly declining mental status, an acute neurological manifestation of which clinicians should be aware.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1999 Oct;109(10):1539-43 [10522919.001]
  • [Cites] Head Neck. 2000 Sep;22(6):550-8 [10941155.001]
  • [Cites] Neurosurg Clin N Am. 2000 Oct;11(4):693-701 [11082179.001]
  • [Cites] Lancet Oncol. 2001 Nov;2(11):683-90 [11902539.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2003 Apr;11(2):112-8 [14515089.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1186-92 [14623748.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):843-9 [1495347.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 May;130(5):567-74 [15138422.001]
  • [Cites] Laryngoscope. 1990 Oct;100(10 Pt 1):1052-8 [2215035.001]
  • [Cites] Cancer. 1989 Jun 15;63(12):2426-8 [2720589.001]
  • [Cites] Cancer. 1979 Sep;44(3):1087-94 [383268.001]
  • [Cites] Ann Otol Rhinol Laryngol. 1977 Nov-Dec;86(6 Pt 1):760-5 [596773.001]
  • [Cites] Head Neck. 1995 Mar-Apr;17(2):114-8 [7558807.001]
  • [Cites] J Neurooncol. 1995 Oct;26(1):35-43 [8583243.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4A):2683-706 [9252701.001]
  • [Cites] Ear Nose Throat J. 1998 Nov;77(11):890-1 [9846465.001]
  • (PMID = 17268590.001).
  • [ISSN] 1531-5010
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1586171
  •  go-up   go-down


5. Amedee RG: Esthesioneuroblastoma: The Princess Margaret Hospital experience. Am J Rhinol Allergy; 2009 Mar 01;23(2):237

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esthesioneuroblastoma: The Princess Margaret Hospital experience.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 29025492.001).
  • [ISSN] 1945-8932
  • [Journal-full-title] American journal of rhinology & allergy
  • [ISO-abbreviation] Am J Rhinol Allergy
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Thompson LD: Olfactory neuroblastoma. Head Neck Pathol; 2009 Sep;3(3):252-9
The Weizmann Institute of Science GeneCards and MalaCards databases. gene/protein/disease-specific - MalaCards for olfactory neuroblastoma .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olfactory neuroblastoma.
  • Few neoplasms are unique to the sinonasal tract, but sinonasal undifferentiated carcinoma and olfactory neuroblastoma are malignant tumors which require unique management.
  • Specifically, olfactory neuroblastoma is a neoplasm that can histologically mimic many tumors within the sinonasal tract, making recognition of this tumor important, as the management frequently requires a bicranial-facial surgical approach, a trephination procedure which can be quite technically difficult and challenging to achieve a good result.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / pathology. Nasal Cavity / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Diagn Pathol. 1996 Aug;13(3):213-41 [8875711.001]
  • [Cites] Mod Pathol. 1996 Jun;9(6):658-63 [8782204.001]
  • [Cites] Acta Neurochir (Wien). 1997;139(9):839-44 [9351988.001]
  • [Cites] Am J Surg Pathol. 1998 Apr;22(4):391-8 [9580174.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1023-7; discussion 1027-8 [9588546.001]
  • [Cites] Laryngoscope. 1999 Oct;109(10):1539-43 [10522919.001]
  • [Cites] Laryngoscope. 2001 Mar;111(3):488-93 [11224781.001]
  • [Cites] Am J Rhinol. 2001 Jul-Aug;15(4):271-9 [11554661.001]
  • [Cites] Lancet Oncol. 2001 Nov;2(11):683-90 [11902539.001]
  • [Cites] Acta Otolaryngol. 2002 Mar;122(2):215-21 [11936917.001]
  • [Cites] Cancer. 2002 Jul 15;95(2):243-8 [12124822.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Jul 1;136(1):53-7 [12165452.001]
  • [Cites] APMIS. 2002 Sep;110(9):639-45 [12529017.001]
  • [Cites] Laryngoscope. 2003 Mar;113(3):502-7 [12616204.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] Cancer. 1977 Jan;39(1):131-8 [832228.001]
  • [Cites] Semin Diagn Pathol. 1989 Nov;6(4):316-28 [2692105.001]
  • [Cites] Am J Clin Pathol. 1990 Nov;94(5):547-53 [1700595.001]
  • [Cites] Semin Diagn Pathol. 2000 Aug;17(3):216-24 [10968707.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):843-9 [1495347.001]
  • [Cites] Ultrastruct Pathol. 1994 Jan-Apr;18(1-2):61-8 [8191648.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1994 Jun;77(6):645-50 [8065732.001]
  • [Cites] Am J Surg Pathol. 1996 Jun;20(6):715-21 [8651351.001]
  • [Cites] Cancer. 1995 Jul 1;76(1):4-19 [8630875.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4A):2683-706 [9252701.001]
  • (PMID = 20596981.001).
  • [ISSN] 1936-0568
  • [Journal-full-title] Head and neck pathology
  • [ISO-abbreviation] Head Neck Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 28
  • [Other-IDs] NLM/ PMC2811627
  •  go-up   go-down


7. Cheng C, Long Xb: [Diagnosis and treatment of esthesioneuroblastoma in the nasal cavity and sinuses]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Oct;30(10):2402-3, 2405
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and treatment of esthesioneuroblastoma in the nasal cavity and sinuses].
  • OBJECTIVE: To discuss the clinical characteristics, diagnosis and treatment of esthesioneuroblastoma (ENB).
  • METHODS: The clinical data of 7 patients with ENB were analyzed retrospectively, and the clinical characteristics, diagnosis, surgical approaches and prognosis of the disease were discussed.
  • CONCLUSION: Early diagnosis of ENB can be difficult.
  • Transnasal-frontal approach with nasal endoscope is effective approach to ENB treatment, and the patients may benefit from postoperative radiotherapy and chemotherapy to improve the prognosis.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory. Nose Neoplasms. Paranasal Sinus Neoplasms
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Nasal Cavity. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20965857.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Mahooti S, Wakely PE Jr: Cytopathologic features of olfactory neuroblastoma. Cancer; 2006 Apr 25;108(2):86-92
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytopathologic features of olfactory neuroblastoma.
  • BACKGROUND: Olfactory neuroblastoma (ONB) is an uncommon neoplasm arising from the olfactory mucosa.
  • Because its cytopathology is largely limited to case reports, the goal was to evaluate a series of ONB cases, compare them with previously reported cases, and with a control group of pulmonary and cutaneous small cell neuroendocrine carcinoma (NEC).
  • METHODS: Six fine-needle aspiration (FNA) biopsies of metastatic ONB and one case with imprint smears of primary ONB were recovered from files.
  • Aspirates from seven FNA cases of metastatic pulmonary small cell NEC and four cases of metastatic Merkel cell carcinoma to the head and neck functioned as a control group and were compared with those of ONB.
  • Aspirates were acquired from soft tissues of the neck (three cases), cervical lymph nodes (two cases), parietal scalp (one case), and imprint of a nasal mass (one case).
  • A correct cytologic diagnosis of metastatic ONB (five cases) or malignant small round cell tumor (one case) was made in six cases.
  • CONCLUSIONS: The cytopathology of metastatic ONB is nonspecific unless fibrillar neuropil is identified.
  • Nonetheless, a cytopathologic diagnosis of metastatic ONB can be made with confidence in nearly all patients if a well documented history of ONB exists.
  • Minus such a clinical context, aspirates of metastatic ONB may be mistaken for metastatic pulmonary small cell NEC, cutaneous neuroendocrine (Merkel cell) carcinoma, and even small cell lymphoma.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / pathology. Esthesioneuroblastoma, Olfactory / secondary. Nasal Cavity / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Carcinoma, Merkel Cell / diagnosis. Carcinoma, Merkel Cell / pathology. Carcinoma, Neuroendocrine / diagnosis. Carcinoma, Neuroendocrine / pathology. Cytodiagnosis. Diagnosis, Differential. Female. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / secondary. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Metastasis / pathology. Scalp. Skin Neoplasms / diagnosis. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16456848.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Sugita Y, Kusano K, Tokunaga O, Mineta T, Abe M, Harada H, Shigemori M: Olfactory neuroepithelioma: an immunohistochemical and ultrastructural study. Neuropathology; 2006 Oct;26(5):400-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olfactory neuroepithelioma: an immunohistochemical and ultrastructural study.
  • Three cases of olfactory neuroepithelioma are presented in this report.
  • Ultrastructurally, the tumor cells had the differentiation features of olfactory epithelium.
  • Olfactory neuroepithelioma is a rare occurrence and it can be very difficult to distinguish olfactory neuroepithelioma from small cell carcinoma, neuroendocrine carcinoma and so-called "olfactory neuroblastoma" on the basis of hematoxylin and eosin stained sections alone.
  • In controversial cases, a diagnosis of olfactory neuroepithelioma must be substantiated by ultrastructural and immunohistochemical findings, particularly regarding the detection of Ber-EP4 and LH-RH immunoreactivity.
  • [MeSH-major] Biomarkers, Tumor / analysis. Nasal Cavity / ultrastructure. Neuroectodermal Tumors, Primitive, Peripheral / ultrastructure. Nose Neoplasms / ultrastructure
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Neuroendocrine / pathology. Carcinoma, Small Cell / pathology. Diagnosis, Differential. Female. Gonadotropin-Releasing Hormone / metabolism. Humans. Immunohistochemistry. Male. Microscopy, Electron, Transmission. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / ultrastructure

  • Genetic Alliance. consumer health - Neuroepithelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17080716.001).
  • [ISSN] 0919-6544
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / human epithelial antigen-125; 33515-09-2 / Gonadotropin-Releasing Hormone
  •  go-up   go-down


10. Iio M, Homma A, Furuta Y, Fukuda S: [Magnetic resonance imaging of olfactory neuroblastoma]. Nihon Jibiinkoka Gakkai Kaiho; 2006 Mar 20;109(3):142-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Magnetic resonance imaging of olfactory neuroblastoma].
  • Olfactory neuroblastoma is an uncommon intranasal tumor originating from olfactory neuroepithelium.
  • Despite the development of electron microscopy and immunohistochemical testing, the pathological diagnosis of this tumor is still difficult because of the wide range of histological features.
  • The purpose of this report was to analyze the MR characteristics of olfactory neuroblastomas.
  • Seventeen patients with olfactory neuroblastoma were treated at Hokkaido University Hospital and a related hospital during the past 25 years.
  • MR images taken in 12 patients and CT images taken in 9 patients with histologically confirmed olfactory neuroblastoma were retrospectively reviewed.
  • In most cases, olfactory neuroblastomas are hypointense on T1-weighted images, hyperintense on T2-weighted images, and show marked homogeneous enhancement with well-demarcated regular margins upon gadolinium enhancement.
  • Although the definite diagnosis is based on histopathology findings and MR features are nonspecific, they may suggest an imaging diagnosis of olfactory neuroblastoma when seen in the superior nasal cavity.
  • MR is superior to CT both in delineating the extent of the tumor and in making an imaging diagnosis.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / diagnosis. Esthesioneuroblastoma, Olfactory / pathology. Magnetic Resonance Imaging. Nasal Cavity / pathology. Nose Neoplasms / diagnosis. Nose Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Image Enhancement. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16615428.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


11. Parker VJ, Morrison JA, Yaeger MJ: Olfactory neuroblastoma in a cat. J Feline Med Surg; 2010 Nov;12(11):867-71
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olfactory neuroblastoma in a cat.
  • Physical examination suggested upper airway disease.
  • Computed tomography revealed the presence of a nasopharyngeal mass.
  • Biopsies obtained via rhinoscopy led to a diagnosis of olfactory neuroblastoma.
  • CLINICAL CHALLENGES: Olfactory neuroblastoma (or esthesioneuroblastoma) is a rare malignant neoplasm that arises from olfactory neuroepithelium.
  • Clinical signs are variable, and diagnosis may prove challenging as this tumor, which is a differential for spontaneous intranasal tumors in cats, may be mistaken for poorly differentiated carcinomas or round cell tumors.
  • Given its rarity, treatment options for this neoplasm have not been thoroughly evaluated and there is no standard treatment protocol.
  • [MeSH-major] Cat Diseases / diagnosis. Esthesioneuroblastoma, Olfactory / veterinary. Nasal Cavity. Nose Neoplasms / veterinary
  • [MeSH-minor] Animals. Cats. Diagnosis, Differential. Male

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 ISFM and AAFP. Published by Elsevier Ltd. All rights reserved.
  • (PMID = 20974404.001).
  • [ISSN] 1532-2750
  • [Journal-full-title] Journal of feline medicine and surgery
  • [ISO-abbreviation] J. Feline Med. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Nishimura H, Ogino T, Kawashima M, Nihei K, Arahira S, Onozawa M, Katsuta S, Nishio T: Proton-beam therapy for olfactory neuroblastoma. Int J Radiat Oncol Biol Phys; 2007 Jul 1;68(3):758-62
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton-beam therapy for olfactory neuroblastoma.
  • PURPOSE: To analyze the feasibility and efficacy of proton-beam therapy (PBT) for olfactory neuroblastoma (ONB) as a definitive treatment, by reviewing our preliminary experience.
  • Olfactory neuroblastoma is a rare disease, and a standard treatment strategy has not been established.
  • Radiation therapy for ONB is challenging because of the proximity of ONBs to critical organs.
  • METHODS AND MATERIALS: A retrospective review was performed on 14 patients who underwent PBT for ONB as definitive treatment at the National Cancer Center Hospital East (Kashiwa, Chiba, Japan) from November 1999 to February 2005.
  • One patient died from disseminated disease.
  • Liquorrhea was observed in one patient with Kadish's stage C disease (widely destroying the skull base).
  • CONCLUSIONS: Our preliminary results of PBT for ONB achieved excellent local control and survival outcomes without serious adverse effects.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / radiotherapy. Nasal Cavity. Neoplasm Recurrence, Local / prevention & control. Nose Neoplasms / radiotherapy. Protons / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17398027.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


13. Mao L, Xia YP, Zhou YN, Dai RL, Yang X, Wang YJ, Duan SJ, Qiao X, Mei YW, Hu B: Activation of sonic hedgehog signaling pathway in olfactory neuroblastoma. Oncology; 2009;77(3-4):231-43
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activation of sonic hedgehog signaling pathway in olfactory neuroblastoma.
  • OBJECTIVES: Sonic hedgehog (Shh) signaling pathway is associated with tumor development; however, the role of Shh signaling in the development of olfactory neuroblastoma (ONB) is unknown.
  • This study aimed to investigate the relationship between the regulation of Shh signaling and the pathogenesis of ONB.
  • METHODS: The expression of Shh signaling components was characterized by immunohistochemistry in human non-tumor olfactory epithelium and ONB specimens, and by RT-PCR and immunoblotting in human ONB cell lines.
  • The impact of the treatment with cyclopamine (a selective inhibitor of the Shh pathway) and/or exogenous Shh on ONB cell proliferation, cycle and apoptosis was examined by MTT, soft agar colony formation and flow cytometry assays, respectively.
  • RESULTS: The expression of Pacthed1, Gli1 and Gli2 was detected in 70, 70, and 65% of human ONB specimens, respectively, and in proportion of ONB cell lines, but not in non-tumor olfactory epithelium.
  • Treatment with cyclopamine inhibited the proliferation and colony formation of ONB cells, induced ONB cell cycle arrest and apoptosis, and down-regulated the expression of Pacthed1, Gli1 and cyclin D1, but up-regulated p21 expression in vitro.
  • CONCLUSION: These data suggest that the Shh signaling pathway is crucial for the growth of ONB.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / metabolism. Hedgehog Proteins / physiology. Nasal Cavity. Nose Neoplasms / metabolism. Signal Transduction / physiology

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • figshare. supplemental materials - Supporting Data and Materials for the article .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19738389.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / GLI2 protein, human; 0 / Hedgehog Proteins; 0 / Kruppel-Like Transcription Factors; 0 / Nuclear Proteins; 0 / Receptors, Cell Surface; 0 / SHH protein, human; 0 / Transcription Factors; 0 / patched receptors
  •  go-up   go-down


14. Gaba RC, Cousins JP, Basil IS, Shadid H, Valyi-Nagy T, Mafee MF: Metastatic Ewing sarcoma masquerading as olfactory neuroblastoma. Eur Arch Otorhinolaryngol; 2006 Oct;263(10):960-2
Genetic Alliance. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic Ewing sarcoma masquerading as olfactory neuroblastoma.
  • Ewing sarcoma is a malignant tumor of bone that rarely spreads to the head and neck.
  • We describe an unusual case of metastatic Ewing sarcoma involving the calvarium mimicking olfactory neuroblastoma, an uncommon neuroectodermal tumor of the anterior skull base.
  • [MeSH-major] Sarcoma, Ewing / diagnosis. Skull Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Esthesioneuroblastoma, Olfactory / diagnosis. Fibula / pathology. Humans. Magnetic Resonance Imaging. Male. Neoplasm Metastasis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Ewing's Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Pediatr Otorhinolaryngol. 1999 May 25;48(3):209-16 [10402117.001]
  • [Cites] Neurol Med Chir (Tokyo). 1999 Dec;39(13):946-9 [10658458.001]
  • [Cites] Clin Radiol. 1995 Sep;50(9):639-43 [7554740.001]
  • (PMID = 16802140.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Kim JW, Kong IG, Lee CH, Kim DY, Rhee CS, Min YG, Kim CW, Chung JH: Expression of Bcl-2 in olfactory neuroblastoma and its association with chemotherapy and survival. Otolaryngol Head Neck Surg; 2008 Nov;139(5):708-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of Bcl-2 in olfactory neuroblastoma and its association with chemotherapy and survival.
  • OBJECTIVE: This study aimed to identify the prognostic value of tumor markers in olfactory neuroblastoma (ONB).
  • STUDY DESIGN AND SETTING: Seventeen patients with ONB (23 tumor specimens) were included.
  • All of the ONB specimens were negative for N-myc.
  • CONCLUSION: Bcl-2 expression was commonly found in ONB and the immunoreactivity for bcl-2 might predict response to neoadjuvant chemotherapy.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / metabolism. Esthesioneuroblastoma, Olfactory / therapy. Nasal Cavity. Nose Neoplasms / metabolism. Nose Neoplasms / therapy. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • Genetic Alliance. consumer health - Neuroblastoma.
  • Genetic Alliance. consumer health - Neuroblastoma 2.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18984268.001).
  • [ISSN] 0194-5998
  • [Journal-full-title] Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
  • [ISO-abbreviation] Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


16. Fury MG, Sherman E, Stambuk H, Haque S, Lisa D, Shen R, Carlson D, Pfister DG: Phase I study of everolimus (E; RAD001) + low-dose weekly cisplatin (C) for patients with advanced solid tumors: Preliminary results. J Clin Oncol; 2009 May 20;27(15_suppl):e14527

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Patients received E per oral for days 1-21 of a 28 day cycle.
  • At DL1, 3 patients were inevaluable (1 withdrawal of consent prior to treatment, 1 disease progression during cycle 1, 1 recurrent diverticulitis during cycle 1) and were replaced.
  • Minor response seen in pulmonary carcinoid (n = 1); prolonged SD ≥ 6 cycles seen in pulmonary carcinoid (n=2), basal cell carcinoma (n=1), and esthesioneuroblastoma (n=1).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27963576.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Hameed S, Jamshed A, Hussain R, Ali M, Iqbal H, Majeed U, Shah MA: Neoadjuvant chemotherapy followed by radiotherapy or chemoradiation for locally advanced nasal and paranasal sinus tumors. J Clin Oncol; 2009 May 20;27(15_suppl):6055

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy followed by radiotherapy or chemoradiation for locally advanced nasal and paranasal sinus tumors.
  • : 6055 Background: The treatment of locally advanced nasal and paranasal sinus tumors is controversial.
  • The disease is chemosensitive and there is increasing interest in the use of chemotherapy with radiation in this group of patients.
  • Our aim was to determine survival in patients with locally advanced nasal and paranasal sinus tumors treated with neoadjuvant chemotherapy followed by radiotherapy or chemoradiation (RT/CRT).
  • METHODS: Between August 2005 and August 2008, 21 patients with AJCC stage III or IV nasal and paranasal sinus tumors were treated with neoadjuvant chemotherapy followed by RT/CRT in our institution.
  • Site of disease was nasal cavity 33% (7), ethamoid sinus 43% (9), maxillary antrum 19% (4), and frontal sinus in 5% (1) of patients.
  • Histopathological diagnosis was squamous cell carcinoma 43% (9), undifferentiated carcinoma 29% (6), adenocarcinoma 19% (4), esthesioneuroblastoma in 9% (2) of patients.
  • Following RT/CRT 86% (18/21) had complete regression of disease.
  • Disease free and overall survival at 40 months was 52% and 63%, respectively.
  • CONCLUSIONS: Gemcitabine cisplatin chemotherapy has good activity in nasal and paranasal sinus tumors.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961932.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Weinreb I, Goldstein D, Irish J, Perez-Ordonez B: Expression patterns of Trk-A, Trk-B, GRP78, and p75NRT in olfactory neuroblastoma. Hum Pathol; 2009 Sep;40(9):1330-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression patterns of Trk-A, Trk-B, GRP78, and p75NRT in olfactory neuroblastoma.
  • Olfactory neuroblastoma is an uncommon neuroectodermal tumor of the sinonasal tract.
  • Most olfactory neuroblastoma behave locally aggressive with 30% recurrence rates.
  • Grading of olfactory neuroblastoma involves a combination of factors with low-grade tumors having better survival than high-grade tumors.
  • The grade does not always predict prognosis, however, as metastases can be seen in all grades of olfactory neuroblastoma.
  • Trk-A, Trk-B, and p75NRT are neurotrophin receptors associated with numerous solid malignancies, particularly pediatric neuroblastoma.
  • Trk-A, p75NRT, and GRP78 overexpression are favorable prognostic factors in pediatric neuroblastoma, whereas Trk-B is associated with a poorer prognosis in these tumors.
  • Olfactory neuroblastoma is clinically distinct from pediatric neuroblastoma but shares some histological features.
  • Trk-A and p75NRT have been demonstrated in olfactory neuroblastoma previously.
  • Trk-B and GRP78 have not been investigated in olfactory neuroblastoma.
  • None of these markers have been correlated with grade or outcome in olfactory neuroblastoma.
  • To investigate the role of Trk-A, Trk-B, p75NRT, and GRP78, a series of 20 olfactory neuroblastomas was stained with these antibodies.
  • Trk-A and Trk-B stained most cases of olfactory neuroblastoma (90% and 85%).
  • Neurotrophin receptors do not appear to have a prognostic role; however, Trk's may play an oncogenic role in olfactory neuroblastoma.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / genetics. Heat-Shock Proteins / genetics. Receptor, Nerve Growth Factor / genetics. Receptor, trkA / genetics. Receptor, trkB / genetics

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19386345.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Heat-Shock Proteins; 0 / Receptor, Nerve Growth Factor; 0 / molecular chaperone GRP78; EC 2.7.10.1 / Receptor, trkA; EC 2.7.10.1 / Receptor, trkB
  •  go-up   go-down


19. Li LY, Chen L, Wang RG, Han DY, Huang DL, Yang WY: [Investigation of surgical managements of olfactory neuroblastoma]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Feb;43(2):89-91
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Investigation of surgical managements of olfactory neuroblastoma].
  • OBJECTIVE: To evaluate the safety and efficacy of transnasal endoscopic resection and craniofacial resection through an external approach for olfactory neuroblastoma (ONB).
  • METHODS: Thirty two patients with ONB treated between 1987 and 2006 were retrospectively reviewed.
  • CONCLUSIONS: Olfactory neuroblastoma can be safely and effectively excised and reconstructed endoscopically with comparable degrees of tissue removal as with external approaches.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / surgery. Nose Neoplasms / surgery. Otorhinolaryngologic Surgical Procedures / methods
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Endoscopy. Female. Humans. Male. Middle Aged. Nasal Cavity. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18510210.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


20. Yuen AP, Fan YW, Fung CF, Hung KN: Endoscopic-assisted cranionasal resection of olfactory neuroblastoma. Head Neck; 2005 Jun;27(6):488-93
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic-assisted cranionasal resection of olfactory neuroblastoma.
  • BACKGROUND: Cranionasal resection was first described in 1997 for the surgical resection of olfactory neuroblastoma.
  • The authors have routinely practiced cranionasal resection since 1996 for resection of all anterior skull base tumors in which the resultant skull base bony defect is limited to the nasal and sinus roof.
  • The aim of this study was to review the results of cranionasal resection for olfactory neuroblastoma.
  • METHODS: The results of cranionasal resection for olfactory neuroblastoma in six patients from 1996 to 2003 were reviewed.
  • Postoperative radiotherapy was given only to the patient with Kadesh stage C disease.
  • Postoperative radiotherapy is not necessary after clear resection of Kadesh A and B tumors.
  • [MeSH-major] Endoscopy. Esthesioneuroblastoma, Olfactory / surgery. Nasal Cavity. Nose Neoplasms / surgery

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley Periodicals, Inc.
  • (PMID = 15880390.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Yao Q, Yue CL, Lü ZC, Han YD, Liu HG: [Olfactory neuroblastoma with unusual structures: a clinical pathologic study]. Zhonghua Bing Li Xue Za Zhi; 2009 Mar;38(3):163-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Olfactory neuroblastoma with unusual structures: a clinical pathologic study].
  • OBJECTIVE: To investigate unusual pathological features of olfactory neuroblastoma (ONB) and its correlation with the clinical prognosis.
  • METHODS: Totally 40 cases of ONB were studied using histology and immunohistochemistry techniques.
  • All the cases of ONB were graded according to Hyams Grading system.
  • RESULTS: ONB consisted of small round tumor cells growing in nests or lobules separated by fibrovascular septa.
  • In addition, 3 cases showed an in-situ form with invasion of tumor into olfactory epithelium, and there was exogenous papillary proliferation seen in 2 cases.
  • CONCLUSIONS: Unusual pathological structures including epithelial structures, in-situ invasion of tumor tissue into the involving olfactory epithelium and exogenous papillary proliferation can be found in ONB, suggesting that ONB may originate from the undifferentiated basal cells of olfactory epithelium, through bipotential differentiation.
  • The presence of tumor necrosis in ONB is a poor prognostic indicator while the presence of mucous cells suggests a good prognosis.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / pathology. Nasal Cavity. Nose Neoplasms / pathology. Olfactory Mucosa / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Chromogranin A / metabolism. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Necrosis. Neoplasm Invasiveness. Neoplasm Recurrence, Local. Phosphopyruvate Hydratase / metabolism. Survival Rate. Synaptophysin / metabolism. Young Adult

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575850.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Chromogranin A; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


22. Kano S, Furuta Y, Homma A, Oridate N, Higuchi E, Suzuki F, Nagahashi T, Sawamura Y, Fukuda S: [Olfactory neuroblastoma: the Hokkaido University experience]. Nihon Jibiinkoka Gakkai Kaiho; 2006 May;109(5):433-9
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Olfactory neuroblastoma: the Hokkaido University experience].
  • Olfactory neuroblastoma is such a rare malignancy that no consensus has been reached on its management.
  • We analyzed 17 patients with olfactory neuroblastoma treated between April 1980 and March 2004--9 men and 8 women, aged 16 to 76 years old(mean: 50.4 years).
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / therapy. Nasal Cavity. Nose Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Hospitals, University / statistics & numerical data. Humans. Japan / epidemiology. Male. Middle Aged. Neoplasm Staging. Prognosis. Salvage Therapy. Survival Rate. Time Factors

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16768158.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


23. Pino Rivero V, Trinidad Ruíz G, González Palomino A, Pardo Romero G, Pantoja Hernández CG, Marcos García M, Montero García C, Blasco Huelva A: [Olfactory neuroblastoma in an old patient. Report of a case]. An Otorrinolaringol Ibero Am; 2005;32(5):429-35
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Olfactory neuroblastoma in an old patient. Report of a case].
  • [Transliterated title] Neuroblastoma olfatorio en paciente de edad avanzada. Presentación de un caso.
  • Olfactory neuroblastoma or esthesioneuroblastoma is a rare embrionary tumor, much more in old patients, which uses to present as a pollipoid mass with nasal obstruction, epistaxis and anosmia of long evolution.
  • We report the case of a 82-year-old male with such symptoms diagnosed by biopsy as neuroblastoma class III according the histologic Hyams grading.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / radiography. Nasal Cavity / radiography. Nose Neoplasms / radiography

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16318085.001).
  • [ISSN] 0303-8874
  • [Journal-full-title] Anales otorrinolaringológicos ibero-americanos
  • [ISO-abbreviation] An Otorrinolaringol Ibero Am
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


24. Wang HL, Fan GK, Lin ZH: [Clinical analysis of 10 cases of olfactory neuroblastoma]. Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 Jan;38(1):103-6
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 10 cases of olfactory neuroblastoma].
  • OBJECTIVE: To review the diagnosis, treatment and prognosis of olfactory neuroblastoma.
  • METHODS: Clinical data were retrospectively reviewed in 10 cases of olfactory neuroblastoma admitted from 1998 to 2002, including data of transmission electron microscopic (TEM) observation in 4 cases.
  • Transmission electron microscope is important for its diagnosis.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / diagnosis. Nasal Cavity. Nose Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19253437.001).
  • [ISSN] 1008-9292
  • [Journal-full-title] Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
  • [ISO-abbreviation] Zhejiang Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


25. Xie MQ, Li ZH, Liu X, Li Y, Xu G: [Retrospective analysis of the effect of intranasal endoscopic resection of olfactory neuroblastoma]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2007 Sep;42(9):669-72
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Retrospective analysis of the effect of intranasal endoscopic resection of olfactory neuroblastoma].
  • OBJECTIVE: To investigate the effectiveness of intranasal endoscopic resection of olfactory neuroblastoma and the significance of assistant radiotherapy.
  • METHODS: Six patients (4 men and 2 women) ranging in age from 9-68 years (median age, 48 years) with olfactory neuroblastoma treated endoscopically at the Third Affiliated Hospital of SUN Yat-sen University between August 2001 and September 2005 were retrospectively analyzed.
  • CONCLUSIONS: With simple approach, excellent visualization, a less operative invasiveness and no scar on face, the endoscopic approach appears to be the method of choice for the treatment of olfactory neuroblastoma.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / surgery. Nasal Cavity. Nose Neoplasms / surgery

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18051565.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


26. Unger F, Haselsberger K, Walch C, Stammberger H, Papaefthymiou G: Combined endoscopic surgery and radiosurgery as treatment modality for olfactory neuroblastoma (esthesioneuroblastoma). Acta Neurochir (Wien); 2005 Jun;147(6):595-601; discussion 601-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined endoscopic surgery and radiosurgery as treatment modality for olfactory neuroblastoma (esthesioneuroblastoma).
  • OBJECT: Treatment of esthesioneuroblastoma (olfactory neuroblastoma) has been considerably improved by microsurgical techniques.
  • A novel therapeutic approach that combines endoscopic sinus surgery and Gamma Knife radiosurgery is presented here.
  • Taking into account the rarity of the disease the present study comprises a relatively large series of patients treated in a similar manner.
  • This series comprises 12 newly diagnosed esthesioneuroblastomas.
  • Paranasal and nasal endoscopic sinus surgery was performed.
  • All patients complained of nasal discharge and crusts.
  • CONCLUSIONS: Based on the favourable results recorded so far, the combination of endoscopic sinus surgery and radiosurgery can be considered a promising treatment option for esthesioneuroblastoma that merits further consideration.
  • [MeSH-major] Endoscopy. Esthesioneuroblastoma, Olfactory / surgery. Nasal Cavity / surgery. Nose Neoplasms / surgery. Radiosurgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Treatment Outcome


27. Woźniak MA, Dobrzyński P, Gutowska A: [Olfactory neuroblastoma in 55 year old woman]. Pol Merkur Lekarski; 2005 Sep;19(111):440-1
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Olfactory neuroblastoma in 55 year old woman].
  • [Transliterated title] Nerwiak wechowy zarodkowy u 55 letniej kobiety.
  • In this article the authors describe a rare case of olfactory neuroblastoma in a 55-year-old woman surgically treated because of nasal polyposis.
  • Three years earlier she had been operated for nasal polyposis on the same side in another ENT department.
  • In histopathological examination it was confirmed to be olfactory neuroblastoma.
  • The tumor was classified as stage B in Kadish classification of olfactory neuroblastoma.
  • The histopathologic diagnosis and CT scan made after the surgery resulted in necessity of further oncological treatment.
  • The olfactory neuroblastoma is rare, difficult to diagnose, malignant, slowly growing tumor arising from the olfactory epithelium in the upper nasal cavity.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory. Nasal Polyps. Nose Neoplasms
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16358902.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


28. Kanno K, Morokuma Y, Tateno T, Hirono Y, Taki K, Osamura RY, Hirata Y: Olfactory neuroblastoma causing ectopic ACTH syndrome. Endocr J; 2005 Dec;52(6):675-81
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olfactory neuroblastoma causing ectopic ACTH syndrome.
  • Although no pituitary mass was detected by MRI of the brain, inferior petrosal sinus sampling showed a step-up of central to peripheral ACTH levels; these data are consistent with the diagnosis of Cushing's disease.
  • Ten months later, a mass was detected in the ethmoid sinus, which was surgically removed.
  • After resection of the ethmoid sinus tumor, her Cushingoid features and hypercortisolemia disappeared, but recurred after enlargement of a second mass in the maxillary sinus.
  • After resection of the maxillary sinus tumor, her hypercortisolemia subsided.
  • Histologically, the tumor tissues from both the ethmoid and maxillary sinus were identical and consistent with the diagnosis of olfactory neuroblastoma.
  • Thus, this is the second rare case with ectopic ACTH syndrome caused by olfactory neuroblastoma thus far reported.
  • [MeSH-major] ACTH Syndrome, Ectopic / etiology. Esthesioneuroblastoma, Olfactory / complications. Nose Neoplasms / complications. Paranasal Sinus Neoplasms / complications
  • [MeSH-minor] Adrenocorticotropic Hormone / analysis. Adrenocorticotropic Hormone / blood. Adult. Circadian Rhythm. Corticotropin-Releasing Hormone / pharmacology. Cushing Syndrome / blood. Cushing Syndrome / diagnosis. Cushing Syndrome / physiopathology. Diagnosis, Differential. Female. Humans. Hydrocortisone / blood. Immunohistochemistry. Pro-Opiomelanocortin / analysis

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16410658.001).
  • [ISSN] 0918-8959
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 66796-54-1 / Pro-Opiomelanocortin; 9002-60-2 / Adrenocorticotropic Hormone; 9015-71-8 / Corticotropin-Releasing Hormone; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


29. Ghaffar S, Salahuddin I: Olfactory neuroblastoma: a case report and review of the literature. Ear Nose Throat J; 2005 Mar;84(3):150-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olfactory neuroblastoma: a case report and review of the literature.
  • Malignant tumors of the nasal cavity are rare.
  • We report the case of an elderly woman who consulted us with a 4-year history of progressive nasal obstruction, occasional epistaxis, facial pain, and watering of the eyes.
  • A diagnosis of olfactory neuroblastoma was established by histopathology and confirmed by immunohistochemistry.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / pathology. Nasal Cavity. Neoplasm Invasiveness / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy, Needle. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging / methods. Nasal Obstruction / diagnosis. Nasal Obstruction / etiology. Neoplasm Staging. Radiotherapy, Adjuvant. Risk Assessment. Tomography, X-Ray Computed / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15871582.001).
  • [ISSN] 0145-5613
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


30. Castelnuovo P, Bignami M, Delù G, Battaglia P, Bignardi M, Dallan I: Endonasal endoscopic resection and radiotherapy in olfactory neuroblastoma: our experience. Head Neck; 2007 Sep;29(9):845-50
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endonasal endoscopic resection and radiotherapy in olfactory neuroblastoma: our experience.
  • BACKGROUND: Our aim was to evaluate the efficacy of a bimodal method of treatment consisting in endoscopic resection followed by radiotherapy in patients with olfactory neuroblastoma (ON).
  • CONCLUSIONS: This method of treatment causes minimal injury to the patients, reduces side effects, and improves the quality of life of those with olfactory neuroblastoma.
  • [MeSH-major] Endoscopy / methods. Esthesioneuroblastoma, Olfactory / radiotherapy. Esthesioneuroblastoma, Olfactory / surgery. Nose Neoplasms / radiotherapy. Nose Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Nasal Cavity. Quality of Life. Radiotherapy, Adjuvant. Retrospective Studies

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley Periodicals, Inc. Head Neck, 2007.
  • (PMID = 17427966.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Mori R, Sakai H, Kato M, Hida T, Nakajima M, Fukuda T, Fukunaga M, Abe T: [Olfactory neuroblastoma with spinal metastasis: case report]. No Shinkei Geka; 2007 May;35(5):503-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Olfactory neuroblastoma with spinal metastasis: case report].
  • Olfactory neuroblastoma is a rare tumor of the nasal cavity.
  • We report a case of olfactory neuroblastoma with cauda equina metastases.
  • A 49-year old male had undergone surgery twice previously; the first for olfactory neuroblastoma in October, 1990, and the second for its intracranial and orbital metastasis in September, 1999.
  • The mass was partially removed and histologically diagnosed as olfactory neuroblastoma metastasis.
  • Olfactory neuroblastoma with spinal metastasis is rare and only 11 cases have been reported in the literature.
  • A very poor prognosis was observed in the patients of olfactory neuroblastoma with spinal metastasis.
  • Olfactory neuroblastoma is a radiosensitive tumor, and radiotherapy for spinal metastasis was reported to be effective.
  • The patient with olfactory neuroblastoma should be observed carefully even though no local recurrence had been detected over 10 years.
  • [MeSH-major] Cauda Equina. Esthesioneuroblastoma, Olfactory / secondary. Esthesioneuroblastoma, Olfactory / surgery. Nasal Cavity. Nose Neoplasms / pathology. Nose Neoplasms / surgery. Peripheral Nervous System Neoplasms / secondary

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17491347.001).
  • [ISSN] 0301-2603
  • [Journal-full-title] No shinkei geka. Neurological surgery
  • [ISO-abbreviation] No Shinkei Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


32. Li X, Liu HG, Xie XJ, Han YD, Li M: [Clinicopathologic study of sinonasal teratocarcinosarcoma and its contrast with olfactory neuroblastoma]. Zhonghua Bing Li Xue Za Zhi; 2008 Jul;37(7):458-64
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic study of sinonasal teratocarcinosarcoma and its contrast with olfactory neuroblastoma].
  • OBJECTIVE: To study the clinicopathologic features, diagnosis and differential diagnosis of sinonasal teratocarcinosarcoma (SNTCS) and olfactory neuroblastoma (ONB), and to discuss the histogenesis and possible relationship between SNTCS and ONB.
  • METHODS: Seven cases of SNTCS and 34 cases of ONB were retrieved from the pathological archives together with one case each of malignant teratoma and immature embryonic tissue at 8 weeks were collected from Beijing Tongren Hospital.
  • In addition, carcinoid, and primitive mesenchymal tissue and the ONB component were also seen.
  • The morphological characteristics of SNTCS comprised fetal clear cell squamous epithelium, carcinosarcoma and the ONB component.
  • The ONB component was positive for Syn, NSE, CD99, NF and CgA to different degrees.
  • The 34 cases of ONB, included 18 men and 16 women, the age ranged from 12 to 72 years (mean 42.8 years).
  • The single case of immature malignant teratoma exhibited primitive nerve tissue, but fetal clear cell squamous epithelium was not found.
  • In the immature embryonic tissue, rudimentary organs were formed, with fetal clear cell squamous epithelium lining present on the nasal and oral cavities surface.
  • CONCLUSIONS: SNTCS is a rare and aggressive malignant neoplasm.
  • Most of ONB are low-grade malignant tumors.
  • Morphological differences are the most important basis to make differentiate SNTCS from ONB.
  • As SNTCS may demonstrate a multiplicity of structures and pleomorphism, inadequate sampling at biopsy, therefore, may lead to errors in diagnosis.
  • SNTCS probably arises from primitive totipotential cells of olfactory/sinonasal membrane, and the relationship between SNTCS and ONB needs further study.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinosarcoma / pathology. Esthesioneuroblastoma, Olfactory / pathology. Nose Neoplasms / pathology. Paranasal Sinus Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged. Nasal Cavity / pathology. Phosphopyruvate Hydratase. Rhabdomyosarcoma / pathology

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19035117.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


33. Park KJ, Kang SH, Lee HG, Chung YG: Olfactory neuroblastoma following treatment for pituitary adenoma. J Neurooncol; 2008 Nov;90(2):237-41
MedlinePlus Health Information. consumer health - Radiation Therapy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olfactory neuroblastoma following treatment for pituitary adenoma.
  • Olfactory neuroblastoma is extremely rare as a second neoplasm.
  • We report an unusual case of olfactory neuroblastoma in a 59-year-old woman who had undergone two operations and received 54 Gy of irradiation for pituitary adenoma 20 years ago.
  • At the time of admission, the patient presented with nasal obstruction and frequent epistaxis.
  • Imaging studies showed a large mass in the nasal cavities and ethmoid sinus, extending to the intracranial area, with no evidence of any recurrence of the previous pituitary adenoma.
  • The tumor was completely excised via a trans-cranial and trans-nasal approach.
  • A diagnosis of olfactory neuroblastoma was established, and the patient was given postoperative chemotherapy.
  • Although relatively uncommon, second neoplasms are an important consideration in the differential diagnosis of patients with new or recurring symptoms after treatment for pituitary adenoma.
  • Furthermore, it is likely that radiation played a critical role in the development of olfactory neuroblastoma in our patient.
  • [MeSH-major] Adenoma / radiotherapy. Esthesioneuroblastoma, Olfactory / etiology. Neoplasms, Second Primary / etiology. Nose Neoplasms / etiology. Pituitary Neoplasms / radiotherapy. Radiotherapy / adverse effects
  • [MeSH-minor] Female. Humans. Magnetic Resonance Imaging / methods. Middle Aged. Nasal Cavity / pathology. Nasal Cavity / radiation effects

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2003 Aug;88(8):3567-72 [12915637.001]
  • [Cites] Oncology. 1990;47(2):199-205 [1969134.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Feb;90(2):800-4 [15562021.001]
  • [Cites] Arch Pathol. 1972 Jan;93(1):26-31 [5006996.001]
  • [Cites] Neurosurg Focus. 2007;23(3):E7 [17961019.001]
  • [Cites] BMJ. 1992 May 23;304(6838):1343-6 [1611331.001]
  • [Cites] Cancer. 1993 Oct 1;72(7):2227-33 [8374881.001]
  • [Cites] J Neurosurg. 1981 Oct;55(4):615-9 [7277008.001]
  • [Cites] Neurosurgery. 1998 Jan;42(1):172-8 [9442520.001]
  • [Cites] Neuroendocrinology. 2006;83(3-4):230-9 [17047388.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):8-34 [9428476.001]
  • [Cites] J Neurosurg. 1998 Jan;88(1):111-5 [9420081.001]
  • [Cites] Pediatr Hematol Oncol. 2001 Oct-Nov;18(7):459-63 [11594709.001]
  • [Cites] Clin Endocrinol (Oxf). 2001 Nov;55(5):613-6 [11894972.001]
  • [Cites] Pediatr Neurosurg. 1994;21 Suppl 1:69-74 [7841081.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] J Neurosurg. 1991 Oct;75(4):564-74 [1885974.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] J Neurosurg. 1990 Oct;73(4):502-12 [2204689.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Oct;55(10):949-55 [1431959.001]
  • [Cites] J Neurosurg. 1995 Jul;83(1):154-62 [7782835.001]
  • [Cites] Neurochirurgia (Stuttg). 1993 Nov;36(6):203-6 [8309496.001]
  • [Cites] J Neurosurg. 1993 Jul;79(1):28-31 [8315464.001]
  • [Cites] Cancer. 2007 Aug 15;110(4):854-60 [17599761.001]
  • (PMID = 18679581.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


34. Ueno H, Kobayashi Y, Yamada K: Olfactory esthesioneuroblastoma treated with orthovoltage radiotherapy in a dog. Aust Vet J; 2007 Jul;85(7):271-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olfactory esthesioneuroblastoma treated with orthovoltage radiotherapy in a dog.
  • On computed tomography examination, a mass was demonstrated in the nasal cavity.
  • Open biopsy of the mass was performed and a diagnosis of olfactory esthesioneuroblastoma was made on histological examination.
  • [MeSH-major] Dog Diseases / radiotherapy. Esthesioneuroblastoma, Olfactory / veterinary
  • [MeSH-minor] Animals. Dogs. Dose-Response Relationship, Radiation. Female. Neoplasm Recurrence, Local. Radiotherapy Dosage. X-Rays

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17615040.001).
  • [ISSN] 0005-0423
  • [Journal-full-title] Australian veterinary journal
  • [ISO-abbreviation] Aust. Vet. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


35. Wang SL, Li SH, Chen WT, Chai CY: Absence of Epstein-Barr virus in olfactory neuroblastoma. Pathology; 2007 Dec;39(6):565-6
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Absence of Epstein-Barr virus in olfactory neuroblastoma.
  • AIMS: The sinonasal region is a frequent site for Epstein-Barr virus (EBV) related tumours, including nasopharyngeal carcinoma, sinonasal undifferentiated carcinoma and malignant lymphoma.
  • Olfactory neuroblastoma is a rare neoplasm, arises from olfactory epithelium, is found in the upper nasal cavity, and may be confused morphologically with the above tumours.
  • Our aim was to determine whether EBV is associated with olfactory neuroblastoma.
  • METHODS: We collected tissue samples for 16 olfactory neuroblastomas over an 11-year period at Kaohsiung Medical University Hospital.
  • RESULTS: None of the epithelial cells in the 16 cases of olfactory neuroblastoma was positive for EBV.
  • CONCLUSIONS: EBV does not play a major role in the aetiology of olfactory neuroblastoma.
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. Esthesioneuroblastoma, Olfactory / secondary. Herpesvirus 4, Human / isolation & purification. Nasal Cavity / pathology. Nose Neoplasms / pathology

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18027259.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / RNA, Viral
  •  go-up   go-down


36. Kim HJ, Kim J, Yoon JH: Retropharyngeal lymph node metastasis from olfactory neuroblastoma: A report of two cases. Eur Arch Otorhinolaryngol; 2006 Aug;263(8):778-82
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retropharyngeal lymph node metastasis from olfactory neuroblastoma: A report of two cases.
  • Olfactory neuroblastoma is a rare, malignant neoplasm arising from the olfactory epithelium.
  • The incidence of cervical lymph node metastasis in olfactory neuroblastoma is variable, and treatment modalities are controversial.
  • Moreover, few reports have been published concerning retropharyngeal lymph node metastasis from olfactory neuroblastoma.
  • We present two cases of olfactory neuroblastoma with retropharyngeal lymph node metastasis.
  • In addition, we provided a review of the current literature regarding olfactory neuroblastoma and retropharyngeal lymph node metastasis from olfactory neuroblastoma.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / secondary. Lymph Nodes / pathology. Nasal Cavity / pathology. Nose Neoplasms / pathology

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1999 Oct;109(10):1539-43 [10522919.001]
  • [Cites] Head Neck. 1992 Nov-Dec;14 (6):477-82 [1468921.001]
  • [Cites] Head Neck. 2005 Feb;27(2):138-49 [15654688.001]
  • [Cites] Arch Otolaryngol. 1983 Dec;109(12):797-802 [6639453.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2004 Feb;130(2):169-73 [14967745.001]
  • [Cites] Radiology. 1990 Jan;174(1):59-64 [2294573.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 May;130(5):567-74 [15138422.001]
  • [Cites] Acta Otolaryngol. 2002 Jul;122(5):556-60 [12206269.001]
  • [Cites] Eur Arch Otorhinolaryngol. 2000 Dec;257(10):561-9 [11195038.001]
  • [Cites] Acta Otolaryngol. 2002 Mar;122(2):215-21 [11936917.001]
  • [Cites] Acta Oncol. 2000;39(2):231-5 [10859017.001]
  • [Cites] Head Neck. 1994 Mar-Apr;16(2):173-80 [8021138.001]
  • [Cites] Head Neck. 2000 May;22(3):275-81 [10748451.001]
  • [Cites] Am J Surg. 1964 Oct;108:500-4 [14211437.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2003 Apr;11(2):112-8 [14515089.001]
  • (PMID = 16691416.001).
  • [ISSN] 0937-4477
  • [Journal-full-title] European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  • [ISO-abbreviation] Eur Arch Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 15
  •  go-up   go-down


37. Wojtarowicz A, Radkowski AS, Tyralik D, Dobroś W: [Extensive olfactory neuroblastoma of the nasal cavity and paranasal sinuses]. Przegl Lek; 2010;67(5):442-4
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extensive olfactory neuroblastoma of the nasal cavity and paranasal sinuses].
  • [Transliterated title] Rozległy nerwiak w chowy zarodkowy jamy nosa i zatok przynosowych.
  • The authors describe a clinical case of extensive olfactory neuroblastoma, comprehensive the nasal cavity, paranasal sinuses and orbit who was treated in Otolaryngology Department of the Regional Hospital in Tarnów.
  • Diagnostic difficulties in olfactory neuroblastoma recognition and value of the immunohistochemical examinations were emphasized.
  • [MeSH-major] Neuroblastoma / diagnosis. Nose Neoplasms / diagnosis. Orbital Neoplasms / diagnosis. Paranasal Sinus Neoplasms / diagnosis
  • [MeSH-minor] Aged. Disease-Free Survival. Female. Humans. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20684358.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


38. Wang SL, Chen WT, Li SH, Li SW, Yang SF, Chai CY: Expression of human telomerase reverse transcriptase and cyclin-D1 in olfactory neuroblastoma. APMIS; 2007 Jan;115(1):17-21
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of human telomerase reverse transcriptase and cyclin-D1 in olfactory neuroblastoma.
  • Olfactory neuroblastoma is an uncommon neoplasm.
  • Typically, these tumors are indolent with long-standing symptomatology, but the fact that the lesions are indeed malignant has been proven by the repeated demonstration that they can metastasize to distant organs.
  • In this study, we collected 16 olfactory neuroblastomas from the Kaohsiung Medical University Hospital.
  • The aim was to investigate the value of immunoexpression of hTERT and cyclin-D1 in correlation with clinicopathologic features of olfactory neuroblastoma.
  • In conclusion, high hTERT expression can be considered a potential indicator of aggressive olfactory neuroblastoma.
  • [MeSH-major] Brain Neoplasms / diagnosis. Cyclins / metabolism. Neuroblastoma / diagnosis. Nose Neoplasms / diagnosis. Telomerase / metabolism
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cyclin D. Humans. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17223847.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cyclin D; 0 / Cyclins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.7.7.49 / TERT protein, human; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


39. Yamate J, Izawa T, Ogata K, Kobayashi O, Okajima R, Kuwamura M, Kotani T, Aoki M: Olfactory neuroblastoma in a horse. J Vet Med Sci; 2006 May;68(5):495-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olfactory neuroblastoma in a horse.
  • An 11-year-old thoroughbred gelding was euthanatized because of right nasal cavity tumor.
  • Based on these findings, this tumor was diagnosed as an olfactory neuroblastoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16757894.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


40. Koo BK, An JH, Jeon KH, Choi SH, Cho YM, Jang HC, Chung JH, Lee CH, Lim S: Two cases of ectopic adrenocorticotropic hormone syndrome with olfactory neuroblastoma and literature review. Endocr J; 2008 Jul;55(3):469-75
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Two cases of ectopic adrenocorticotropic hormone syndrome with olfactory neuroblastoma and literature review.
  • Olfactory neuroblastomas are rare, slow-growing malignant tumors, usually diagnosed at advanced stages.
  • Ectopic adrenocorticotropic hormone (ACTH) syndrome caused by an olfactory neuroblastoma is extremely rare.
  • We reported two Korean women who suffered from ectopic ACTH syndrome (EAS) caused by olfactory neuroblastomas.
  • The first patient was a 66-year-old woman who had been diagnosed as olfactory neuroblastoma and refused the management two years before and the second patient was a 37-year-old woman on chemotherapy for olfactory neuroblastoma.
  • [MeSH-major] ACTH Syndrome, Ectopic / radiography. Esthesioneuroblastoma, Olfactory / secretion. Nasal Cavity / radiography. Nose Neoplasms / secretion

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18469486.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 9002-60-2 / Adrenocorticotropic Hormone; WI4X0X7BPJ / Hydrocortisone
  • [Number-of-references] 36
  •  go-up   go-down


41. Lee JY, Kim HK: Primary olfactory neuroblastoma originating from the inferior meatus of the nasal cavity. Am J Otolaryngol; 2007 May-Jun;28(3):196-200
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary olfactory neuroblastoma originating from the inferior meatus of the nasal cavity.
  • Olfactory neuroblastoma is a rare malignant tumor of the nasal cavity arising from the olfactory neuroepithelium.
  • It usually presents as a polypoid mass high in the nasal vault including the cribriform plate, superior turbinate, and superior portion of nasal septum.
  • An 89-year-old man visited our office with symptoms of occasional left nasal bleeding and obstruction.
  • Biopsy was performed, and the diagnosis of olfactory neuroblastoma was confirmed by histopathologic examination and immunohistochemical staining.
  • The tumor was resected via medial maxillectomy, and the final pathologic report established that it was primary olfactory neuroblastoma that occurred from the inferior meatus.
  • In this report, a literature review was performed on the pathologic characteristics and prognosis of the tumor, and possible hypotheses that olfactory neuroblastoma has originated from the inferior meatus were discussed.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / pathology. Nasal Cavity / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Aged, 80 and over. Humans. Male. Neoplasm Invasiveness. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17499140.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Chan LP, Wang LF, Tai CF, Wu CC, Kuo WR: Huge sphenoid sinus olfactory neuroblastoma: a case report. Kaohsiung J Med Sci; 2009 Feb;25(2):87-92
Genetic Alliance. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Huge sphenoid sinus olfactory neuroblastoma: a case report.
  • Intranasal or paranasal sinus olfactory neuroblastoma is a rare malignant neoplasm of olfactory neuroepithelial origin, accounting for approximately 5% of paranasal sinus cancers.
  • Most of the presenting symptoms include nasal obstruction, nasal bleeding, anosmia, rhinorrhea, and headache.
  • In this present report, we describe a 79-year-old man who presented with bilateral nasal congestion for more than 1 year.
  • Nasoendoscopy showed a huge, smooth, mucosal tumor in the nasopharynx with extension to the posterior nasal septum.
  • The tumor was completely resected under endonasal endoscopy and the pathology revealed olfactory neuroblastoma.
  • Olfactory neuroblastomas usually arise in the cribriform plate and superior turbinate.
  • However, the origin and isolation of olfactory neuroblastomas to the sphenoid sinus is exceedingly rare.
  • Only four cases of olfactory neuroblastoma isolated in the sphenoid sinus have been described in English literature and the frequency of presenting symptoms with cranial neuropathies and headache.
  • We report a case of primary sphenoid sinus olfactory neuroblastoma with the greatest enlargement reported to date.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / pathology. Nasal Cavity. Paranasal Sinus Neoplasms / pathology. Sphenoid Sinus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19321412.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China (Republic : 1949- )
  • [Number-of-references] 11
  •  go-up   go-down


43. Takagi M, Shiraiwa K, Kusuoka O, Tamura K: A Case of Olfactory Neuroblastoma Induced in A Rat by N-Nitrosobis(2-hydroxypropyl)amine. J Toxicol Pathol; 2010 Jun;23(2):111-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Case of Olfactory Neuroblastoma Induced in A Rat by N-Nitrosobis(2-hydroxypropyl)amine.
  • In the present paper, a case of olfactory neuroblastoma (ONB) induced in a rat by BHP is described.
  • Histologically, the tumor arose in the posterior nasal cavity and consisted of small round cells and elongate cells with scant basophilic cytoplasm.
  • These results indicate that the present tumor is the first case of ONB induced in a rat by BHP treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22272021.001).
  • [ISSN] 1881-915X
  • [Journal-full-title] Journal of toxicologic pathology
  • [ISO-abbreviation] J Toxicol Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Other-IDs] NLM/ PMC3234646
  • [Keywords] NOTNLM ; BHP / N-nitrosobis(2-hydroxypropyl)amine / olfactory neuroblastoma / rat
  •  go-up   go-down


44. Ozsahin M, Gruber G, Olszyk O, Karakoyun-Celik O, Pehlivan B, Azria D, Roelandts M, Kaanders JH, Cengiz M, Krengli M, Matzinger O, Zouhair A: Outcome and prognostic factors in olfactory neuroblastoma: a rare cancer network study. Int J Radiat Oncol Biol Phys; 2010 Nov 15;78(4):992-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome and prognostic factors in olfactory neuroblastoma: a rare cancer network study.
  • PURPOSE: To assess the outcome in patients with olfactory neuroblastoma (ONB).
  • METHODS AND MATERIALS: Seventy-seven patients treated for nonmetastatic ONB between 1971 and 2004 were included.
  • Sixty-eight patients presented with N0 (88%) disease.
  • The 5-year overall survival (OS), disease-free survival (DFS), locoregional control, and local control were 64%, 57%, 62%, and 70%, respectively.
  • In univariate analyses, favorable factors were Kadish A or B disease, T1-T3 tumors, no nodal involvement, curative surgery, R0/R1 resection, and RT-dose 54 Gy or higher.
  • CONCLUSION: In this multicenter retrospective study, patients with ONB treated with R0 or R1 surgical resection followed by at least 54-Gy postoperative RT had the best outcome.
  • Novel strategies including concomitant chemotherapy and/or higher dose RT should be prospectively investigated in this rare disease for which local failure remains a problem.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / therapy. Nose Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Analysis of Variance. Combined Modality Therapy / methods. Disease-Free Survival. Female. Humans. Male. Middle Aged. Nasal Cavity / pathology. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20231062.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


45. Josephs L, Jones L, Marenette L, McKeever P: Cushing's Syndrome: An Unusual Presentation of Olfactory Neuroblastoma. Skull Base; 2008 Jan;18(1):73-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cushing's Syndrome: An Unusual Presentation of Olfactory Neuroblastoma.
  • A pituitary MRI was performed, which revealed a normal pituitary; however, a large mass was seen centered in the ethmoid and paranasal sinuses with a significant amount of extension into surrounding structures.
  • A biopsy was performed and pathology of the specimen was consistent with esthesioneuroblastoma.
  • Immunohistochemical staining further defined the tumor as an ACTH-secreting esthesioneuroblastoma.
  • This case demonstrates the successful diagnosis and treatment of a rare neoplasm.
  • Ectopic ACTH syndrome due to esthesioneuroblastoma is extremely uncommon with only five other cases being discussed in the literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet Oncol. 2001 Nov;2(11):683-90 [11902539.001]
  • [Cites] Endocr Pract. 2004 Mar-Apr;10(2):119-24 [15256328.001]
  • [Cites] Endocr J. 2005 Dec;52(6):675-81 [16410658.001]
  • [Cites] Ultrastruct Pathol. 1994 Jan-Apr;18(1-2):61-8 [8191648.001]
  • [Cites] Arch Intern Med. 1986 Sep;146(9):1731-5 [3753113.001]
  • [Cites] Am J Med. 1986 Nov;81(5):911-6 [3776995.001]
  • [Cites] J Neuropathol Exp Neurol. 1985 Jan;44(1):18-31 [3965624.001]
  • [Cites] Ann Pathol. 1987;7(2):137-42 [3620028.001]
  • (PMID = 18592016.001).
  • [ISSN] 1531-5010
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2435464
  • [Keywords] NOTNLM ; Cushing's syndrome / Ectopic ACTH syndrome / esthesioneuroblastoma / olfactory Neuroblastoma
  •  go-up   go-down


46. Bellizzi AM, Bourne TD, Mills SE, Stelow EB: The cytologic features of sinonasal undifferentiated carcinoma and olfactory neuroblastoma. Am J Clin Pathol; 2008 Mar;129(3):367-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The cytologic features of sinonasal undifferentiated carcinoma and olfactory neuroblastoma.
  • Olfactory neuroblastoma (ONB) is an uncommon neuroectodermal tumor of the superior nasal cavity.
  • Upon examining these lesions, a broad differential diagnosis of poorly differentiated round cell tumors must be considered.
  • The cytologic features of SNUC and ONB have been rarely reported.
  • We searched our cytology files for cases of SNUC and ONB and assessed the following: cellularity, architecture, cytoplasm, cell size, nuclear contours, nucleoli, chromatin, anisonucleosis/anisocytosis, mitotic activity, background, and nuclear crush.
  • The 10 cases of ONB exhibited cellularity, cellular arrangement, and chromatin similar to SNUC.
  • We believe that in the appropriate clinical context, a specific cytologic diagnosis should be possible.
  • [MeSH-major] Carcinoma / pathology. Esthesioneuroblastoma, Olfactory / pathology. Nasal Cavity / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Carcinoma, Small Cell / pathology. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Middle Aged


47. Diensthuber M, Potinius M, Rodt T, Stan AC, Welkoborsky HJ, Samii M, Schreyögg J, Lenarz T, Stöver T: Expression of bcl-2 is associated with microvessel density in olfactory neuroblastoma. J Neurooncol; 2008 Sep;89(2):131-9
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of bcl-2 is associated with microvessel density in olfactory neuroblastoma.
  • Activation of the erythropoietin receptor (EpoR) by Epo leads to elevated expression of the anti-apoptotic protein, bcl-2, which has recently been shown to promote angiogenesis in malignant tumors.
  • Expression of HIF-1alpha, Epo, EpoR, and bcl-2 was studied by immunohistochemistry in a series of 20 olfactory neuroblastoma (ONB) samples.
  • Immunohistochemical analysis revealed robust expression of HIF-1alpha, Epo, EpoR, and bcl-2 in ONB.
  • Expression of HIF-1alpha, Epo, Epo-R, and bcl-2 may play a functional role in ONB pathogenesis.
  • Our data suggest that bcl-2 may act as a stimulator of angiogenesis in ONB, and thus represents a novel target for anti-angiogenic treatment strategies in the therapy of ONB.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / metabolism. Esthesioneuroblastoma, Olfactory / pathology. Nasal Cavity / pathology. Neovascularization, Pathologic. Nose Neoplasms / metabolism. Nose Neoplasms / pathology. Proto-Oncogene Proteins c-bcl-2 / metabolism

  • Genetic Alliance. consumer health - Neuroblastoma.
  • Genetic Alliance. consumer health - Neuroblastoma 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1995 Jul 1;76(1):4-19 [8630875.001]
  • [Cites] FASEB J. 2002 Sep;16(11):1453-5 [12205045.001]
  • [Cites] Ann N Y Acad Sci. 2004 Dec;1028:133-42 [15650239.001]
  • [Cites] FASEB J. 1996 May;10(7):760-8 [8635693.001]
  • [Cites] Otol Neurotol. 2004 May;25(3):359-65 [15129118.001]
  • [Cites] Cancer Res. 1989 Dec 1;49(23):6449-65 [2684393.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1789-806 [12759237.001]
  • [Cites] Breast Cancer Res Treat. 1995;36(2):169-80 [8534865.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):309-14 [11181778.001]
  • [Cites] Blood. 1993 Jan 15;81(2):293-8 [8422456.001]
  • [Cites] N Engl J Med. 1971 Nov 18;285(21):1182-6 [4938153.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Clin Cancer Res. 2001 Jun;7(6):1661-8 [11410504.001]
  • [Cites] Mol Vis. 2005 Sep 01;11:697-704 [16163267.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5063-9 [15958549.001]
  • [Cites] Lancet Oncol. 2001 Nov;2(11):683-90 [11902539.001]
  • [Cites] Clin Cancer Res. 2006 Dec 1;12 (23 ):6894-900 [17145806.001]
  • [Cites] Histopathology. 2007 Apr;50(5):636-41 [17394500.001]
  • [Cites] Cancer Sci. 2005 Jul;96(7):394-402 [16053510.001]
  • [Cites] Blood. 1999 Sep 15;94(6):1864-77 [10477715.001]
  • [Cites] Cancer Res. 1992 Dec 15;52(24):6940-4 [1458483.001]
  • [Cites] Blood. 1996 Sep 1;88(5):1576-82 [8781412.001]
  • [Cites] Otol Neurotol. 2007 Jun;28(4):559-65 [17429338.001]
  • [Cites] Clin Cancer Res. 2000 May;6(5):1900-8 [10815914.001]
  • [Cites] Cancer. 2002 May 15;94(10):2745-55 [12173346.001]
  • [Cites] Cancer Lett. 2004 Oct 28;214(2):243-51 [15363551.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 7;93(3):208-13 [11158189.001]
  • [Cites] Mol Cancer Ther. 2007 Jan;6(1):101-11 [17237270.001]
  • [Cites] Int J Cancer. 2000 Apr 15;86(2):188-96 [10738245.001]
  • [Cites] Trends Mol Med. 2002;8(4 Suppl):S62-7 [11927290.001]
  • [Cites] Trends Mol Med. 2003 Mar;9(3):109-17 [12657432.001]
  • [Cites] Cancer Res. 2001 May 1;61(9):3561-5 [11325818.001]
  • [Cites] Exp Cell Res. 1999 Nov 25;253(1):143-56 [10579919.001]
  • [Cites] Cancer Res. 2001 Oct 15;61(20):7394-8 [11606368.001]
  • [Cites] Nat Rev Mol Cell Biol. 2008 Jan;9(1):47-59 [18097445.001]
  • (PMID = 18431543.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD31; 0 / Hypoxia-Inducible Factor 1, alpha Subunit; 0 / Ki-67 Antigen; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Erythropoietin; 11096-26-7 / Erythropoietin
  •  go-up   go-down


48. Nomoto S, Shioyama Y, Ohga S, Nakamura K, Honda H: Advanced olfactory neuroblastoma treated with combined conventional and hypofractionated stereotactic radiotherapy. J Cancer Res Ther; 2010 Oct-Dec;6(4):581-4
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Advanced olfactory neuroblastoma treated with combined conventional and hypofractionated stereotactic radiotherapy.
  • Three patients with olfactory neuroblastoma (ONB) of the nasal and/or paranasal cavity were treated with a combination of conventional radiotherapy (RT) and hypofractionated stereotactic radiation therapy (SRT).
  • [MeSH-major] Neuroblastoma / radiotherapy. Nose Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21358109.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


49. Diaz EM Jr, Johnigan RH 3rd, Pero C, El-Naggar AK, Roberts DB, Barker JL, DeMonte F: Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center. Head Neck; 2005 Feb;27(2):138-49
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olfactory neuroblastoma: the 22-year experience at one comprehensive cancer center.
  • BACKGROUND: Olfactory neuroblastoma (ONB) is a rare tumor arising from the olfactory neuroepithelium.
  • METHODS: Thirty patients treated for ONB at The University of Texas M. D.
  • The diagnosis of ONB was histologically confirmed for each patient.
  • Nine patients whose disease was initially stage C had a recurrence.
  • Anderson Cancer Center approach to ONB is complete surgical resection, usually involving a craniofacial approach, with postoperative radiation therapy.
  • This approach seems to be curative in early-stage disease.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / diagnosis. Esthesioneuroblastoma, Olfactory / therapy. Nasal Cavity. Nose Neoplasms / diagnosis. Nose Neoplasms / therapy
  • [MeSH-minor] Academic Medical Centers. Adolescent. Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Rate. Texas. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 Wiley Periodicals, Inc.
  • (PMID = 15654688.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Kutluhan A, Yilmaz N, Yakut F, Yurttaş V, Uğraş S: [Treatment of olfactory neuroblastoma via subfrontal and midfacial degloving approaches: a case report]. Kulak Burun Bogaz Ihtis Derg; 2008;18(1):56-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of olfactory neuroblastoma via subfrontal and midfacial degloving approaches: a case report].
  • A 12-year-old girl presented with complaints of nasal obstruction and a right infraorbital swelling.
  • A biopsy obtained from the right nasal passage revealed olfactory neuroblastoma.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / surgery. Nasal Cavity / surgery. Nose Neoplasms / surgery
  • [MeSH-minor] Biopsy. Child. Female. Humans. Nasal Obstruction / etiology. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18443406.001).
  • [ISSN] 1300-7475
  • [Journal-full-title] Kulak burun boğaz ihtisas dergisi : KBB = Journal of ear, nose, and throat
  • [ISO-abbreviation] Kulak Burun Bogaz Ihtis Derg
  • [Language] tur
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


51. Díez-Villalba R, González-Ruiz M, Izquierdo-Vázquez C, Molina-Quirós C, Colmenero-Ruiz M, Ramos-Amador A, Jordano-Luna L, Mora-de-Oñate J, Sanz-Fernández R: [Ophthalmic presentation of two cases of esthesioneuroblastoma]. Arch Soc Esp Oftalmol; 2008 May;83(5):317-20
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ophthalmic presentation of two cases of esthesioneuroblastoma].
  • [Transliterated title] Debut oftalmológico de dos casos de estesioneuroblastoma.
  • PURPOSE/METHOD: To report the ophthalmologic presentation of two cases of esthesioneuroblastoma (ENB).
  • A paranasal sinus mass was biopsied in one case and a nasal mass biopsied in the other.
  • ENB is a rare malignant tumour and its presentation with ophthalmologic symptoms and signs is very infrequent.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / complications. Nasal Cavity. Nose Neoplasms / complications

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18464181.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


52. Kim BJ, Kim DW, Kim SW, Han DH, Kim DY, Rhee CS, Lee CH: Endoscopic versus traditional craniofacial resection for patients with sinonasal tumors involving the anterior skull base. Clin Exp Otorhinolaryngol; 2008 Sep;1(3):148-53

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The number of malignant and benign lesions was 40 and 6 cases respectively.
  • The most common diagnosis was olfactory neuroblastoma occurring in 41% of the cases followed by squamous cell carcinoma and malignant melanoma.
  • The overall five-year survival rate for patients with malignant tumors of the anterior skull base was 47.4%.
  • Out of 19 patients with olfactory neuroblastomas, 10 patients had TCFR and six among them died of their disease.
  • Nine patients underwent ECFR, and none of them died of their disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Rhinol. 2007 Jan-Feb;21(1):89-94 [17283568.001]
  • [Cites] Laryngoscope. 2001 Mar;111(3):488-93 [11224781.001]
  • [Cites] Skull Base. 2006 Feb;16(1):15-8 [16880896.001]
  • [Cites] Laryngoscope. 2006 Jun;116(6):982-6 [16735899.001]
  • [Cites] Laryngorhinootologie. 2005 Dec;84(12):884-91 [16358197.001]
  • [Cites] Neurosurg Focus. 2002 May 15;12(5):e4 [16119902.001]
  • [Cites] Otolaryngol Clin North Am. 2005 Feb;38(1):133-44, ix [15649504.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2257-60 [15484215.001]
  • [Cites] Am J Surg. 1963 Nov;106:698-703 [14078719.001]
  • [Cites] Am J Rhinol. 1999 Jul-Aug;13(4):303-10 [10485018.001]
  • [Cites] Am J Otolaryngol. 1997 Nov-Dec;18(6):431-3 [9395024.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1029-37 [9588547.001]
  • [Cites] Neurosurgery. 1996 Mar;38(3):471-9; discussion 479-80 [8837798.001]
  • [Cites] Head Neck. 1994 Jul-Aug;16(4):307-12 [8056574.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1992 Sep;118(9):913-7 [1503715.001]
  • [Cites] Am J Surg. 1988 Sep;156(3 Pt 1):187-90 [3421426.001]
  • [Cites] Otolaryngol Head Neck Surg. 1989 Dec;101(6):665-9 [2512555.001]
  • [Cites] Am J Surg. 1987 Oct;154(4):352-8 [3661836.001]
  • [Cites] Head Neck Surg. 1986 Jul-Aug;8(6):429-35 [3721885.001]
  • [Cites] Am J Rhinol. 2004 Jul-Aug;18(4):239-46 [15490571.001]
  • [Cites] Laryngoscope. 2003 Dec;113(12):2086-90 [14660907.001]
  • [Cites] Otolaryngol Clin North Am. 2001 Dec;34(6):1123-42, ix [11728937.001]
  • [Cites] Laryngoscope. 2006 Oct;116(10):1749-54 [17003718.001]
  • (PMID = 19434247.001).
  • [ISSN] 1976-8710
  • [Journal-full-title] Clinical and experimental otorhinolaryngology
  • [ISO-abbreviation] Clin Exp Otorhinolaryngol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2671747
  • [Keywords] NOTNLM ; Endoscopic craniofacial resection / Nose neoplasms / Skull base
  •  go-up   go-down


53. Nakao K, Watanabe K, Fujishiro Y, Ebihara Y, Asakage T, Goto A, Kawahara N: Olfactory neuroblastoma: long-term clinical outcome at a single institute between 1979 and 2003. Acta Otolaryngol Suppl; 2007 Dec;(559):113-7
Genetic Alliance. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olfactory neuroblastoma: long-term clinical outcome at a single institute between 1979 and 2003.
  • CONCLUSIONS: The progression of olfactory neuroblastoma showed a biphasic pattern.
  • A high local failure rate suggests that craniofacial resection followed by postoperative radiotherapy should still be the standard treatment for olfactory neuroblastoma.
  • OBJECTIVE: The aim of this study was to evaluate factors associated with survival and local control of olfactory neuroblastoma in the long run and to estimate treatment strategies.
  • PATIENTS AND METHODS: Twelve patients (seven men and five women) who had undergone initial curative treatment for olfactory neuroblastoma were retrospectively analyzed.
  • RESULTS: Cause-specific 10-year survival was 64.8%, while disease-free 10-year survival remained 28.6%.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / epidemiology. Esthesioneuroblastoma, Olfactory / therapy. Peripheral Nervous System Neoplasms / epidemiology. Peripheral Nervous System Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Agents / therapeutic use. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Neoplasm Recurrence, Local. Neurosurgical Procedures

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18340581.001).
  • [ISSN] 0365-5237
  • [Journal-full-title] Acta oto-laryngologica. Supplementum
  • [ISO-abbreviation] Acta Otolaryngol Suppl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


54. Scińska A, Korkosz A, Sienkiewicz-Jarosz H, Kukwa W, Jezewska E, Kukwa A: [Olfactory neuroblastoma (esthesioneuroblastoma): etiopatogenesis, diagnosis, and treatment]. Otolaryngol Pol; 2006;60(6):849-58
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Olfactory neuroblastoma (esthesioneuroblastoma): etiopatogenesis, diagnosis, and treatment].
  • [Transliterated title] Neuroblastoma nerwu wechowego (esthesioneuroblastoma): etiopatogeneza, diagnostyka i leczenie.
  • INTRODUCTION: Esthesioneuroblastoma is a malignant tumour arising from the olfactory epithelium located in the upper part of the nasal cavities.
  • Recent clinical and preclinical studies shed more light on etiopathogenesis, diagnosis, and treatment of this rare malignancy.
  • RESULTS: Molecular studies indicate basal progenitor cells of the olfactory epithelium as the origin of esthesioneuroblastoma.
  • Tumour symptoms are related to its location and typically include: epistaxis, nasal obstruction, olfactory and ophtalmic disturbances as well as craniofacial pain.
  • Esthesioneuroblastoma should be differentiated from embryonic rhabdomyosarcoma, Ewing's sarcoma, melanoma, lymphoma, and pericytoma.
  • CONCLUSIONS: Esthesioneuroblastoma is a rare malignant tumour arising from the olfactory epithelium.
  • Early diagnosis and interdisciplinary approach to treatment is vital in the management of the tumour.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / diagnosis. Esthesioneuroblastoma, Olfactory / therapy. Nasal Cavity. Nose Neoplasms / diagnosis. Nose Neoplasms / therapy
  • [MeSH-minor] Diagnosis, Differential. Humans. Neoplasm Staging. Olfactory Mucosa

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357662.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Poland
  • [Number-of-references] 82
  •  go-up   go-down


55. Klepin HD, McMullen KP, Lesser GJ: Esthesioneuroblastoma. Curr Treat Options Oncol; 2005 Nov;6(6):509-18
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esthesioneuroblastoma.
  • Esthesioneuroblastoma is a rare tumor for which the published literature does not provide an evidence-based consensus treatment approach.
  • Multimodality therapy including a combination of surgery and radiation appears to provide the best disease-free and overall survival.
  • Chemotherapy should not be used as single-modality therapy for initial treatment but may provide additional benefit when used in combination with radiation and surgery, particularly in advanced-stage disease.
  • Combination chemotherapy should be considered as initial therapy for unresectable tumors and metastatic disease, and as salvage therapy in disease recurrence.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / therapy. Nasal Cavity / pathology. Nose Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Humans. Neoplasm Staging

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):486-91 [12243826.001]
  • [Cites] Neurosurgery. 1993 May;32(5):706-14; discussion 714-5 [8492845.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2257-60 [15484215.001]
  • [Cites] Laryngoscope. 2003 Mar;113(3):502-7 [12616204.001]
  • [Cites] Cancer. 2002 Jul 15;95(2):243-8 [12124822.001]
  • [Cites] Cancer. 1994 May 15;73(10):2556-62 [8174053.001]
  • [Cites] Br J Radiol. 2002 Apr;75(892):356-61 [12000695.001]
  • [Cites] Neurosurg Focus. 2002 May 15;12 (5):e4 [16119902.001]
  • [Cites] Cancer. 2004 Sep 15;101(6):1437-44 [15368332.001]
  • [Cites] Laryngoscope. 2000 Apr;110(4):635-40 [10764010.001]
  • [Cites] Head Neck. 2005 Feb;27(2):138-49 [15654688.001]
  • [Cites] Strahlenther Onkol. 2003 Apr;179(4):233-40 [12707712.001]
  • [Cites] Lancet Oncol. 2001 Nov;2(11):683-90 [11902539.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4A):2683-706 [9252701.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 May;130(5):567-74 [15138422.001]
  • [Cites] Laryngoscope. 2003 Dec;113(12):2086-90 [14660907.001]
  • [Cites] Head Neck. 2000 Sep;22(6):550-8 [10941155.001]
  • [Cites] Acta Neurochir (Wien). 2005 Jun;147(6):595-601; discussion 601-2 [15806328.001]
  • [Cites] Acta Otolaryngol. 2003 Apr;123(3):433-9 [12737303.001]
  • [Cites] Neurosurg Clin N Am. 2000 Oct;11(4):693-701 [11082179.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2003 Apr;11(2):112-8 [14515089.001]
  • [Cites] J Neurooncol. 2004 Oct;70(1):73-5 [15527110.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):843-9 [1495347.001]
  • [Cites] Cancer. 2002 May 15;94(10):2623-34 [12173330.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1186-92 [14623748.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1029-37 [9588547.001]
  • (PMID = 16242055.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 29
  •  go-up   go-down


56. Gil-Carcedo E, Gil-Carcedo LM, Vallejo LA, de Campos JM: [Esthesioneuroblastoma treatment]. Acta Otorrinolaringol Esp; 2005 Nov;56(9):389-95
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Esthesioneuroblastoma treatment].
  • [Transliterated title] Tratamiento del estesioneuroblastoma. Revisión de la literatura.
  • INTRODUCTION: Esthesioneuroblastoma is an uncommon malignancy of the olfactory neuroepithelium.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / therapy. Nasal Cavity. Nose Neoplasms / therapy

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16353783.001).
  • [ISSN] 0001-6519
  • [Journal-full-title] Acta otorrinolaringológica española
  • [ISO-abbreviation] Acta Otorrinolaringol Esp
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 67
  •  go-up   go-down


57. Kiyota N, Tahara M, Fujii S, Kawashima M, Ogino T, Minami H, Hayashi R, Ohtsu A: Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma: a retrospective analysis of 12 cases. Cancer; 2008 Feb 15;112(4):885-91
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nonplatinum-based chemotherapy with irinotecan plus docetaxel for advanced or metastatic olfactory neuroblastoma: a retrospective analysis of 12 cases.
  • BACKGROUND: The efficacy and safety of chemotherapy with irinotecan plus docetaxel were retrospectively evaluated for olfactory neuroblastoma.
  • METHODS: Twelve patients with histologically proven advanced or metastatic olfactory neuroblastoma were treated with chemotherapy with irinotecan plus docetaxel at the study institution between 2001 and 2005.
  • Of these, 7 patients with locoregional disease and no prior radiotherapy received irinotecan plus docetaxel followed by definitive radiotherapy, 1 with photon radiotherapy and 6 with proton radiotherapy, whereas 3 patients with distant metastases and 2 with locoregional disease who had received prior radiotherapy received irinotecan plus docetaxel only.
  • Of the 7 patients with locoregional disease also receiving definitive radiotherapy, the 2-year survival rate was 100% and 6 patients were alive at the time of last follow-up.
  • CONCLUSIONS: Chemotherapy for olfactory neuroblastoma with irinotecan plus docetaxel is safe and manageable.
  • Induction chemotherapy followed by definitive radiotherapy may represent a promising option for patients with locally advanced olfactory neuroblastoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esthesioneuroblastoma, Olfactory / drug therapy. Neuroblastoma / drug therapy
  • [MeSH-minor] Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Retrospective Studies. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Cancer 2008. (c) 2008 American Cancer Society.
  • (PMID = 18189294.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


58. Shukla RC, Singh PK, Senthil S, Pathak R: Esthesioneuroblastoma: a case report. Nepal Med Coll J; 2010 Jun;12(2):128-32
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esthesioneuroblastoma: a case report.
  • Esthesioneuroblastoma (olfactory neuroblastoma) is an uncommon neuroectodermal tumor.
  • Patients often present with nasal obstruction, rhinorrhea, recurrent epistaxis, hyposmia, or anosmia.
  • We report a case of esthesioneuroblastoma involving bilateral nasal cavity leading to bilateral nasal obstruction, epistaxis and proptosis of the right eye associated with decreased visual acquity on that eye and loss of smell.
  • A diffuse nontender, 6x6 cms swelling with illdefined margins was seen over the nasal bridge, extending superiorly to glabella and laterally to right maxillary region.
  • X-ray PNS showed soft tissue mass in the nasal cavity with destruction of nasal septum, intense periosteal reaction with destruction of right maxillary wall and extension to right orbit.
  • CT scan of paranasal sinuses showed 8.5 x 4.9 x 7.8 cms irregularly marginated heterogeneous iso- to hyper dense soft tissue mass lesion with extensive adjacent bony destruction and spiculated periosteal reaction involving bilateral nasal cavity and anterior cranial fossa.
  • Biopsy from right nasal mass showed neuroblastoma.
  • The modified Kadish staging system, lymph node status, treatment modality, and age are useful predictors of survival in patients who present with esthesioneuroblastoma.
  • Excellent outcomes for esthesioneuroblastoma are achievable.
  • Long-term follow-up is necessary because of the extended interval for recurrent disease; unlike most sinonasal malignancies, surgical salvage is possible.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory. Nasal Cavity. Nose Neoplasms
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Male. Nasal Obstruction / etiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21222414.001).
  • [Journal-full-title] Nepal Medical College journal : NMCJ
  • [ISO-abbreviation] Nepal Med Coll J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Nepal
  •  go-up   go-down


59. Zeng M, Cui Y, Wu C: [Expression of SSTR2 and P-STAT3 in human olfactory neuroblastoma]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Aug;24(15):690-2
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of SSTR2 and P-STAT3 in human olfactory neuroblastoma].
  • OBJECTIVE: To detect the expression and relationship between somatostatin receptor 2 (SSTR2) and phosphorylated STAT3 (P-STAT3) in human olfactory neuroblastoma (ONB) and adjacent normal olfactory nerve tissue.
  • METHOD: Immunohistochemical (IHC) staining was used to detect the expression of SSTR2 and P-STAT3 in tumor and adjacent normal olfactory nerve tissue from 11 ONB patients.
  • CONCLUSION: Lower expression of SSTR2 and activation of STAT3 in ONB cells might contribute to the development of ONB.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / metabolism. Nose Neoplasms / metabolism. Receptors, Somatostatin / metabolism. STAT3 Transcription Factor / metabolism

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20942237.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Receptors, Somatostatin; 0 / STAT3 Transcription Factor; 0 / STAT3 protein, human; 0 / somatostatin receptor 2
  •  go-up   go-down


60. Faragalla H, Weinreb I: Olfactory neuroblastoma: a review and update. Adv Anat Pathol; 2009 Sep;16(5):322-31
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Olfactory neuroblastoma: a review and update.
  • Olfactory neuroblastoma (ONB) is a malignant neuroectodermal tumor that typically occurs in the superior nasal cavity.
  • In addition, problems in sampling, preservation, and clinical localization may make the diagnosis more challenging.
  • A large group of tumors may show morphologic overlap with ONB, with some mimicking low-grade tumors, whereas others mimic high-grade tumors.
  • This differential diagnosis has important treatment and prognostic implications.
  • Further complicating the issue is that many of the mimics themselves may show great morphologic and immunophenotypic variability.
  • This manuscript will review the typical clinical and pathologic features of ONB, address the great variability of ONB in our experience, will focus on the differential diagnosis and report on recent findings in these tumors including molecular genetics where applicable.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / pathology. Nasal Cavity / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Keratins / metabolism. S100 Proteins / metabolism

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19700942.001).
  • [ISSN] 1533-4031
  • [Journal-full-title] Advances in anatomic pathology
  • [ISO-abbreviation] Adv Anat Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / S100 Proteins; 68238-35-7 / Keratins
  • [Number-of-references] 59
  •  go-up   go-down


61. Kim HJ, Cho HJ, Kim KS, Lee HS, Kim HJ, Jung E, Yoon JH: Results of salvage therapy after failure of initial treatment for advanced olfactory neuroblastoma. J Craniomaxillofac Surg; 2008 Jan;36(1):47-52
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of salvage therapy after failure of initial treatment for advanced olfactory neuroblastoma.
  • INTRODUCTION: Olfactory neuroblastoma is a very aggressive tumour with high rates of locoregional recurrence and distant metastasis.
  • In this study, we present our experience and treatment outcomes for salvage therapy in patients with recurrent olfactory neuroblastoma.
  • MATERIAL AND METHODS: We retrospectively analysed 17 patients treated for advanced olfactory neuroblastoma during the last 15 years.
  • RESULTS: The disease-free 5-year survival rate was 48% in all patients and 42% in the 17 patients with recurrence or distant metastasis.
  • In 15% of patients with a clinical stage N0 at initial diagnosis, nodal recurrence developed and was successfully treated with salvage therapy.
  • CONCLUSION: Complete surgical resection, including craniofacial resection and postoperative radiotherapy without elective neck dissection, is the preferred approach in the treatment of advanced olfactory neuroblastoma.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / secondary. Esthesioneuroblastoma, Olfactory / therapy. Nasal Cavity. Neoplasm Recurrence, Local / therapy. Nose Neoplasms / therapy. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neck Dissection. Prognosis. Radiotherapy, High-Energy. Retrospective Studies

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312791.001).
  • [ISSN] 1010-5182
  • [Journal-full-title] Journal of cranio-maxillo-facial surgery : official publication of the European Association for Cranio-Maxillo-Facial Surgery
  • [ISO-abbreviation] J Craniomaxillofac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


62. Mrad K, Mansouri D, Driss M, Sassi S, Abbes I, Ben Ayed F, Ben Romdhane K: Esthesioneuroblastoma metastatic to the breast in a young woman. Acta Cytol; 2005 Jul-Aug;49(4):427-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esthesioneuroblastoma metastatic to the breast in a young woman.
  • We report an unusual breast metastasis originating in an olfactory neuroblastoma.
  • CASE: A breast metastasis from esthesioneuroblastoma occurred in a 20-year-old woman 2 years after the onset of the disease.
  • Because we were unaware of the past history at the time of the cytologic analysis, a definitive diagnosis was made only after pathologic study.
  • CONCLUSION: Esthesioneuroblastoma metastatic to the breast must be considered in the differential diagnosis of breast metastases.
  • Fine needle aspiration, in conjunction with clinical information, can be effective in the diagnosis of esthesioneuroblastoma metastatic to the breast.
  • [MeSH-major] Breast Neoplasms / diagnosis. Esthesioneuroblastoma, Olfactory / diagnosis. Nasal Cavity / pathology. Nose Neoplasms / diagnosis


63. Torres Muros B, Pérez Arcos JA, Alvarex Rey I, Lazarich Valdés A, Verge González J, Rodríguez Baró JG: [Esthesioneuroblastoma. Description of a case and review of the literature]. An Otorrinolaringol Ibero Am; 2006;33(5):513-20
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Esthesioneuroblastoma. Description of a case and review of the literature].
  • [Transliterated title] Estesioneuroblastoma. Presentación de un caso clínico y revisión de la bibliografía.
  • The esthesioneuroblastoma is a malignant and rare type of the nasal cavity.
  • Affected patients usually present with a progressive nasal obstruction, rhinorrea and epistaxis.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / diagnosis. Nasal Cavity / pathology. Nose Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17091865.001).
  • [ISSN] 0303-8874
  • [Journal-full-title] Anales otorrinolaringológicos ibero-americanos
  • [ISO-abbreviation] An Otorrinolaringol Ibero Am
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


64. Bourne TD, Bellizzi AM, Stelow EB, Loy AH, Levine PA, Wick MR, Mills SE: p63 Expression in olfactory neuroblastoma and other small cell tumors of the sinonasal tract. Am J Clin Pathol; 2008 Aug;130(2):213-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p63 Expression in olfactory neuroblastoma and other small cell tumors of the sinonasal tract.
  • Olfactory neuroblastoma (ONB) is a rare neoplasm of the head and neck region that is included in the differential diagnosis of other sinonasal tract malignancies.
  • We studied the usefulness of using p63 as an aid in the diagnosis of ONB and other tumors of the sinonasal region.
  • The specimens were 14 ONBs; 4 nasopharyngeal carcinomas (NPCs), nonkeratinizing subtype; 2 NPCs, undifferentiated subtype; 10 sinonasal undifferentiated carcinomas (SNUCs); 7 malignant melanomas; and 2 extranodal natural killer (NK)/T-cell lymphomas.
  • We observed p63 expression in 5 ONBs (36%), 4 nonkeratinizing NPCs (100%), 1 undifferentiated NPC (50%), 2 SNUCs (20%); 0 malignant melanomas (0%); and 1 extranodal NK/T-cell lymphoma (50%).
  • While all cases of NPC with positive staining for p63 showed strong and diffuse immunoreactivity, the ONB, SNUC, and lymphoma cases with positive immunoreactivity showed only focal staining for p63.
  • No p63 expression was observed in malignant melanoma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Esthesioneuroblastoma, Olfactory / diagnosis. Membrane Proteins / analysis. Nasal Cavity. Nose Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Male. Middle Aged. Nasopharyngeal Neoplasms / diagnosis. Paranasal Sinus Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18628089.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CKAP4 protein, human; 0 / Membrane Proteins
  •  go-up   go-down


65. Freeman SR, Mitra S, Malik TH, Flanagan P, Selby P: Expression of somatostatin receptors in arginine vasopressin hormone-secreting olfactory neuroblastoma--report of two cases. Rhinology; 2005 Mar;43(1):61-5
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of somatostatin receptors in arginine vasopressin hormone-secreting olfactory neuroblastoma--report of two cases.
  • OBJECTIVE: Arginine vasopressin hormone-secreting olfactory neuroblastomas are extremely rare, with fewer than twenty cases reported in the literature.
  • CONCLUSIONS: This report demonstrates the potential use of somatastatin analogues in the investigation, follow-up and treatment of patients with olfactory neuroblastoma.
  • [MeSH-major] Arginine Vasopressin / secretion. Esthesioneuroblastoma, Olfactory / metabolism. Esthesioneuroblastoma, Olfactory / secretion. Nasal Cavity. Nose Neoplasms / metabolism. Nose Neoplasms / secretion. Receptors, Somatostatin / biosynthesis

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15844504.001).
  • [ISSN] 0300-0729
  • [Journal-full-title] Rhinology
  • [ISO-abbreviation] Rhinology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Receptors, Somatostatin; 113-79-1 / Arginine Vasopressin
  •  go-up   go-down


66. Zhao LJ, Gao L, Xu GZ, Li SY, Xiao GL: [Prognostic factors and outcome of esthesioneuroblastoma]. Zhonghua Zhong Liu Za Zhi; 2005 Sep;27(9):561-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors and outcome of esthesioneuroblastoma].
  • OBJECTIVE: To investigate the clinical feature, prognostic factors and the appropriate treatment modality of esthesioneuroblastoma (ENB).
  • In this series, 3 patients had modified Kadish stage A disease, 15 stage B, 22 stage C, and 9 stage D lesion.
  • Overall survival (OS) and disease free survival (DFS) were calculated using Kaplan-Meier method.
  • The 5-year OS of patients with modified Kadish stage A or B disease and those with stage C or D was 78.4% and 49.7% (chi(2) = 2.10, P = 0.15), and the 5-year DFS was 47.1% and 38.4% (chi(2) = 0.08, P = 0.78), respectively.
  • CONCLUSION: Esthesioneuroblastoma is more prevalent in the young male adults than female, usually with locally advanced stage lesion when first diagnosed.
  • Radiotherapy plays an important role in the management of the disease.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / radiotherapy. Esthesioneuroblastoma, Olfactory / surgery. Nose Neoplasms / radiotherapy. Nose Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Nasal Cavity. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16438858.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


67. Sajko T, Rumboldt Z, Talan-Hranilovic J, Radic I, Gnjidic Z: Primary sellar esthesioneuroblastoma. Acta Neurochir (Wien); 2005 Apr;147(4):447-8; discussion 448
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary sellar esthesioneuroblastoma.
  • We describe an extremely rare case of a primary intrasellar esthesioneuroblastoma.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory. Pituitary Neoplasms

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15711771.001).
  • [ISSN] 0001-6268
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  •  go-up   go-down


68. Mintzer DM, Zheng S, Nagamine M, Newman J, Benito M: Esthesioneuroblastoma (Olfactory Neuroblastoma) with Ectopic ACTH Syndrome: a multidisciplinary case presentation from the Joan Karnell cancer center of Pennsylvania Hospital. Oncologist; 2010;15(1):51-8
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esthesioneuroblastoma (Olfactory Neuroblastoma) with Ectopic ACTH Syndrome: a multidisciplinary case presentation from the Joan Karnell cancer center of Pennsylvania Hospital.
  • The case of a patient with recurrent esthesioneuroblastoma complicated by ectopic adrenocorticotropic hormone production is presented, including the workup and management of this uncommon complication of an uncommon disease.
  • [MeSH-major] ACTH Syndrome, Ectopic / etiology. Adrenocorticotropic Hormone / metabolism. Esthesioneuroblastoma, Olfactory / secretion. Esthesioneuroblastoma, Olfactory / therapy. Nose Neoplasms / secretion. Nose Neoplasms / therapy
  • [MeSH-minor] Anti-Inflammatory Agents / therapeutic use. Antifungal Agents / therapeutic use. Antineoplastic Agents, Alkylating / therapeutic use. Antineoplastic Agents, Hormonal / therapeutic use. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Humans. Hydrocortisone / blood. Hydrocortisone / therapeutic use. Immunohistochemistry. Ketoconazole / therapeutic use. Magnetic Resonance Imaging. Male. Middle Aged. Nasal Cavity. Neoplasm Invasiveness. Neoplasm Recurrence, Local / drug therapy. Octreotide / therapeutic use

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. KETOCONAZOLE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2005 Aug;90(8):4955-62 [15914534.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2257-60 [15484215.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Feb;91(2):371-7 [16303835.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Feb;132(2):134-8 [16490869.001]
  • [Cites] Otolaryngol Pol. 2006;60(6):849-58 [17357662.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Mar;133(3):276-80 [17372086.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):885-91 [18189294.001]
  • [Cites] Endocr J. 2008 Jul;55(3):469-75 [18469486.001]
  • [Cites] Neurosurgery. 2008 Jul;63(1 Suppl 1):ONS44-52; discussion ONS52-3 [18728603.001]
  • [Cites] J Neurooncol. 2008 Nov;90(2):201-4 [18633576.001]
  • [Cites] Head Neck. 2008 Dec;30(12):1607-14 [18798301.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):357-8 [11773199.001]
  • [Cites] Lancet Oncol. 2001 Nov;2(11):683-90 [11902539.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1186-92 [14623748.001]
  • [Cites] J Endocrinol Invest. 2003 Aug;26(8):710-7 [14669823.001]
  • [Cites] Endocr Pract. 2004 Mar-Apr;10(2):119-24 [15256328.001]
  • [Cites] Arch Otolaryngol. 1977 Sep;103(9):514-7 [332133.001]
  • [Cites] Ann Pathol. 1987;7(2):137-42 [3620028.001]
  • [Cites] Neurosurgery. 1993 May;32(5):706-14; discussion 714-5 [8492845.001]
  • [Cites] Ultrastruct Pathol. 1994 Jan-Apr;18(1-2):61-8 [8191648.001]
  • [Cites] J Neurooncol. 1995 Oct;26(1):35-43 [8583243.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Feb 6;93(3):1038-43 [8577710.001]
  • [Cites] Metabolism. 1996 Aug;45(8 Suppl 1):129-31 [8769407.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4A):2683-706 [9252701.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1023-7; discussion 1027-8 [9588546.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Apr;84(4):1193-202 [10199752.001]
  • [Cites] J Neurooncol. 2004 Oct;70(1):73-5 [15527110.001]
  • [Cites] Endocr J. 2005 Dec;52(6):675-81 [16410658.001]
  • (PMID = 20053760.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antifungal Agents; 0 / Antineoplastic Agents, Alkylating; 0 / Antineoplastic Agents, Hormonal; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 9002-60-2 / Adrenocorticotropic Hormone; R9400W927I / Ketoconazole; RWM8CCW8GP / Octreotide; WI4X0X7BPJ / Hydrocortisone
  • [Other-IDs] NLM/ PMC3227887
  •  go-up   go-down


69. Wang J, Wang R, Han D, Yang W: [Esthesioneuroblastoma in children]. Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2006 Jun;20(11):491-3
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Esthesioneuroblastoma in children].
  • OBJECTIVE: To summarize the clinical characterization of esthesioneuroblastoma in children and adolescence.
  • METHOD: The esthesioneuroblastoma in children treated in our hospital from 1993 to 2004 were retrospectively evaluated, and thorough literature review of patients with esthesioneuroblastoma was performed by searching for the key word "esthesioneuroblastoma" in CHKD and in Pub Med between 1994-2004, also looking for its reference.
  • The main symptoms were nasal occlusion, proptosis, epistaxis, headache and the main location of disease were the intranasal, ethmoid sinus, orbital, anterior cranial fossa.
  • CONCLUSION: Esthesioneuroblastoma in children is very rare and combined surgery and radiotherapy should be selected.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory. Nose Neoplasms

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16929827.001).
  • [Journal-full-title] Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology
  • [ISO-abbreviation] Lin Chuang Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  •  go-up   go-down


70. Koch M, Constantinidis J, Dimmler A, Strauss C, Iro H: [Long-term experiences in the therapy of esthesioneuroblastoma]. Laryngorhinootologie; 2006 Oct;85(10):723-30
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term experiences in the therapy of esthesioneuroblastoma].
  • [Transliterated title] Langzeit-Erfahrungen in der Therapie des Asthesioneuroblastoms.
  • BACKGROUND: Esthesioneuroblastoma is a rare and clinically variable tumor of nasal sinus and skull base and challenging for modern multidisciplinary therapy.
  • PATIENTS AND METHODS: Between 1975 and 2001 26 patients were treated after the diagnosis of esthesioneuroblastoma was established.
  • Disease specific 10- and 15-year-survival according to the estimation of Kaplan-Meier was 76.2 %.
  • Salvage therapy was performed in 5 cases (71.4 %) with a success rate and a 15-year survival each of 60 %.
  • CONCLUSIONS: Therapy of esthesioneuroblastoma is challenging because of rarity and biologic variability of the tumor and and because of lack of a standard therapy.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / therapy. Nasal Cavity. Nose Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Agents, Phytogenic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Dactinomycin / administration & dosage. Dactinomycin / therapeutic use. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Etoposide / administration & dosage. Etoposide / therapeutic use. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Ifosfamide / therapeutic use. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Analysis. Time Factors. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16673299.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; UM20QQM95Y / Ifosfamide; VAIA protocol
  •  go-up   go-down


71. Porter AB, Bernold DM, Giannini C, Foote RL, Link MJ, Olsen KD, Moynihan TJ, Buckner JC: Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma. J Neurooncol; 2008 Nov;90(2):201-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective review of adjuvant chemotherapy for esthesioneuroblastoma.
  • BACKGROUND: Esthesioneuroblastoma (ENB) is a rare tumor arising from the olfactory epithelium in the upper nasal cavity.
  • METHODS: A retrospective review of 76 patients treated at the Mayo Clinic for esthesioneuroblastoma from 1976 to 2003 was performed to evaluate adjuvant chemotherapy (AC) in these patients.
  • CONCLUSIONS: This small retrospective series suggests that adjuvant therapy for patients with high grade, Stage C esthesioneuroblastoma is of benefit following complete resection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esthesioneuroblastoma, Olfactory / drug therapy. Nasal Cavity. Nose Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 1990 Apr;13(2):139-43 [2180272.001]
  • [Cites] Neurosurgery. 1993 May;32(5):706-14; discussion 714-5 [8492845.001]
  • [Cites] Cancer. 2004 Nov 15;101(10):2257-60 [15484215.001]
  • [Cites] Cancer. 1984 Mar 1;53(5):1036-41 [6362834.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Jun;136(6):998-1002 [17547995.001]
  • [Cites] Head Neck. 2005 Feb;27(2):138-49 [15654688.001]
  • [Cites] Lancet Oncol. 2001 Nov;2(11):683-90 [11902539.001]
  • [Cites] Cancer. 1989 Feb 15;63(4):638-42 [2536584.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1023-7; discussion 1027-8 [9588546.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Nov 15;27(4):835-42 [8244813.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Feb;132(2):134-8 [16490869.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):357-8 [11773199.001]
  • [Cites] Cancer. 2002 May 15;94(10):2623-34 [12173330.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1997 Jan;123(1):34-40 [9006501.001]
  • (PMID = 18633576.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


72. Preusser M, Hutterer M, Sohm M, Koperek O, Elandt K, Dieckmann K, Prayer D, Marosi C: Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate. J Neurooncol; 2010 Apr;97(2):305-8
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Disease stabilization of progressive olfactory neuroblastoma (esthesioneuroblastoma) under treatment with sunitinib mesylate.
  • Olfactory neuroblastoma (esthesioneuroblastoma) is a rare neoplasm of the olfactory epithelium in the upper nasal cavity.
  • Here, we report the case of a 69-year-old man who presented with massive progression of a metastatic esthesioneuroblastoma after endonasal resection, functional neck dissection, and radiotherapy of local and distant tumor relapses.
  • Using this drug, significant improvement of clinical symptoms, disease stabilization, and recovery from Karnofsky index of 40% to 70% could be achieved in the absence of significant adverse drug effects.
  • The patient died 15 months after initiation of sunitinib therapy due to complications of a traumatic femoral neck fracture without evidence of tumor progression.
  • Sunitinib should be considered for palliative therapy of advanced esthesioneuroblastoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Esthesioneuroblastoma, Olfactory / drug therapy. Indoles / therapeutic use. Nasal Cavity / pathology. Neoplasm Recurrence, Local / drug therapy. Nose Neoplasms / drug therapy. Pyrroles / therapeutic use

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurooncol. 2008 Nov;90(2):201-4 [18633576.001]
  • [Cites] Nat Rev Drug Discov. 2006 Apr;5(4):279-80 [16628834.001]
  • [Cites] Cancer. 2008 Feb 15;112(4):885-91 [18189294.001]
  • [Cites] Lancet Oncol. 2001 Nov;2(11):683-90 [11902539.001]
  • [Cites] JAMA. 2006 Jun 7;295(21):2516-24 [16757724.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1023-7; discussion 1027-8 [9588546.001]
  • [Cites] Clin Ther. 2007 Jul;29(7):1338-53 [17825686.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1329-38 [17046465.001]
  • [Cites] J Neurooncol. 2004 Oct;70(1):73-5 [15527110.001]
  • (PMID = 19820899.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; V99T50803M / sunitinib
  •  go-up   go-down


73. Chou S, Varikatt W, Dexter M, Ng T: Extraventricular neurocytoma with atypical features and ganglionic differentiation. J Clin Neurosci; 2010 Jul;17(7):920-2

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report an EVN arising from the right frontal lobe near the olfactory tract in a 34-year-old male with worsening chronic epilepsy.
  • Our patient's tumour exhibited many uncommon features including ganglionic differentiation, increased mitotic activity and a high proliferative index.
  • We discuss the important differential diagnoses given the site of the tumour as well as the differentiating features from olfactory neuroblastoma, oligodendroglioma, anaplastic ganglioglioma and supra-tentorial primitive neuroectodermal tumour.
  • [MeSH-major] Cell Differentiation. Frontal Lobe / pathology. Ganglia / pathology. Neurocytoma / pathology. Olfactory Pathways / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20399667.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


74. Benfari G, Fusconi M, Ciofalo A, Gallo A, Altissimi G, Celani T, De Vincentiis M: Radiotherapy alone for local tumour control in esthesioneuroblastoma. Acta Otorhinolaryngol Ital; 2008 Dec;28(6):292-7
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy alone for local tumour control in esthesioneuroblastoma.
  • Esthesioneuroblastoma is an uncommon tumour.
  • Due to its low incidence, this neoplasm is difficult to evaluate and its treatment remains a matter of debate.
  • With reference to the treatment of esthesioneuroblastoma, 55 patients submitted only to radiotherapy have been selected from publications of internationally indexed literature between 1979 and 2006.
  • There was no evidence of disease in: 6/6 stage A patients with a median follow-up period of 103.6 months, 7/12 stage B patients with a median followup period of 120 months, and 7/37 stage C patients with a median follow-up period of 77.3 months.
  • A total of 27 patients died due to tumour-related causes and 5 due to intercurrent disease, while 3 patients were alive with disease (local recurrence and cervical lymph node metastasis).
  • In conclusion, esthesioneuroblastoma is a malignant tumour which grows both locoregionally and distantly.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / radiotherapy. Nasal Cavity. Nose Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Retrospective Studies. Time Factors. Treatment Failure. Treatment Outcome

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):155-60 [11163509.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Jan;136(1):104-7 [17210343.001]
  • [Cites] Lancet Oncol. 2001 Nov;2(11):683-90 [11902539.001]
  • [Cites] J Neurooncol. 2002 Sep;59(3):217-26 [12241118.001]
  • [Cites] Laryngoscope. 2003 Mar;113(3):502-7 [12616204.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] J Laryngol Otol. 1979 Mar;93(3):285-92 [429906.001]
  • [Cites] Cancer. 1979 Sep;44(3):1087-94 [383268.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Mar;6(3):349-52 [7390908.001]
  • [Cites] Laryngoscope. 1988 Aug;98(8 Pt 1):872-6 [3398665.001]
  • [Cites] Am J Clin Oncol. 1988 Dec;11(6):672-8 [3055935.001]
  • [Cites] Cancer. 1989 Jun 15;63(12):2426-8 [2720589.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):843-9 [1495347.001]
  • [Cites] Eur J Cancer. 1994;30A(12):1757-60 [7880600.001]
  • [Cites] J Laryngol Otol. 1996 Nov;110(11):1012-6 [8944873.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4A):2683-706 [9252701.001]
  • [Cites] Acta Neurochir (Wien). 2005 Jun;147(6):595-601; discussion 601-2 [15806328.001]
  • [Cites] Laryngoscope. 2001 Mar;111(3):488-93 [11224781.001]
  • (PMID = 19205593.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 20
  • [Other-IDs] NLM/ PMC2689543
  •  go-up   go-down


75. Das S: A role for biological optimization within the current treatment planning paradigm. Med Phys; 2009 Oct;36(10):4672-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The method is demonstrated in the context of a prostate cancer case and olfactory neuroblastoma case.
  • In the olfactory neuroblastoma case, the target was closely surrounded by the eyes, optic nerves, chiasm, and brainstem.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19928099.001).
  • [ISSN] 0094-2405
  • [Journal-full-title] Medical physics
  • [ISO-abbreviation] Med Phys
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Wei YX, Han DM: [Management of nasal skull-base neoplasms with endoscopic minimally invasive technique: a report of 36 cases]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2008 Dec;43(12):915-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of nasal skull-base neoplasms with endoscopic minimally invasive technique: a report of 36 cases].
  • OBJECTIVE: To discuss the indication, efficacy and safety of endoscopic minimally invasive surgery technique in the management of nasal skull-base neoplasms.
  • METHODS: Thirty-six patients with nasal skull base neoplasms were treated from January 2000 to Jun 2004 under nasal endoscopy, including 16 nasopharyngeal fibroangioma, 8 sinus osteofibroma, 8 pituitary adenoma, 4 olfactory neuroblastoma.
  • All olfactory neuroblastoma and 2 pituitary adenoma received radiotherapy after operation.
  • RESULTS: Total or most of nasopharyngeal fibroangioma, sinus osteofibroma, olfactory neuroblastoma and pituitary adenoma were excised.
  • CONCLUSIONS: When the indications are selected appropriately, nasal skull-base neoplasms, including benign and malignant, can be well treated with nasal endoscopic minimally invasive surgery.
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Fibroma, Ossifying / surgery. Humans. Male. Middle Aged. Minimally Invasive Surgical Procedures. Nasopharyngeal Neoplasms / surgery. Neuroblastoma / surgery. Nose / surgery. Olfactory Nerve / pathology. Pituitary Neoplasms / surgery. Young Adult

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19141243.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


77. Loy AH, Reibel JF, Read PW, Thomas CY, Newman SA, Jane JA, Levine PA: Esthesioneuroblastoma: continued follow-up of a single institution's experience. Arch Otolaryngol Head Neck Surg; 2006 Feb;132(2):134-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esthesioneuroblastoma: continued follow-up of a single institution's experience.
  • OBJECTIVES: To analyze outcomes and to provide follow-up for our increasing patient cohort with esthesioneuroblastoma.
  • PATIENTS: Fifty consecutive patients diagnosed as having esthesioneuroblastoma were treated with a standardized protocol during a 28-year period.
  • Patients with tumors staged Kadish A or B received preoperative radiotherapy followed by craniofacial resection, while patients with Kadish stage C disease were treated with preoperative sequential chemotherapy and radiotherapy followed by a craniofacial resection.
  • RESULTS: The disease-free survival was 86.5% and 82.6% at 5 and 15 years, respectively.
  • There were 17 patients (34%) who developed recurrent disease, most of which was locoregional (12 patients [71%]).
  • Of these 17 patients, 7 (41%) underwent successful salvage surgery, while 3 remain alive with disease.
  • CONCLUSIONS: Excellent outcomes for esthesioneuroblastoma are achievable.
  • Long-term follow-up is necessary because of the extended interval for recurrent disease; unlike most sinonasal malignancies, surgical salvage is possible.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Esthesioneuroblastoma, Olfactory. Nasal Cavity. Neurosurgical Procedures / methods. Nose Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Retrospective Studies. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16490869.001).
  • [ISSN] 0886-4470
  • [Journal-full-title] Archives of otolaryngology--head & neck surgery
  • [ISO-abbreviation] Arch. Otolaryngol. Head Neck Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


78. Zhang M, Zhou L, Wang DH, Huang WT, Wang SY: Diagnosis and management of esthesioneuroblastoma. ORL J Otorhinolaryngol Relat Spec; 2010;72(2):113-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis and management of esthesioneuroblastoma.
  • AIMS: Our purpose was to evaluate the diagnosis and combined modality treatment of esthesioneuroblastoma treated at 1 institution.
  • METHODS: A retrospective analysis of clinical information regarding presentation, immunohistochemical results, treatment and outcome was performed on 21 patients with esthesioneuroblastoma.
  • RESULTS: Two patients had Kadish A, 12 had Kadish B and 7 had Kadish C disease.
  • Generally, the patients were treated with preoperative radiotherapy (Kadish A and Kadish B) and preoperative chemoradiotherapy (Kadish C) after the initial biopsy, followed by surgery.
  • Surgical approaches (n = 21) consisted of 12 lateral rhinotomies, 5 craniofacial resections, 3 endoscopic sinus surgeries and 1 midfacial degloving approach.
  • CONCLUSIONS: Esthesioneuroblastoma is an uncommon malignant tumor.
  • Thorough histological evaluation is the key to correct diagnosis and differentiation.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory. Nasal Cavity / pathology. Nose Neoplasms

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20453548.001).
  • [ISSN] 1423-0275
  • [Journal-full-title] ORL; journal for oto-rhino-laryngology and its related specialties
  • [ISO-abbreviation] ORL J. Otorhinolaryngol. Relat. Spec.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chromogranin A; 0 / Mucin-1; 0 / S100 Proteins; 0 / Synaptophysin; 0 / Vimentin; 68238-35-7 / Keratins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


79. Tramacere F, Bambace S, De Luca MC, Castagna R, Francavilla MC, Leone A, Monastero S, Fucilli F, Pili G, Portaluri M: Esthesioneuroblastoma treated with external radiotherapy. Case report. Acta Otorhinolaryngol Ital; 2008 Aug;28(4):215-7
Genetic Alliance. consumer health - Esthesioneuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esthesioneuroblastoma treated with external radiotherapy. Case report.
  • Esthesioneuroblastoma is a rare tumour arising from the olfactory epithelium of the nasal vault which frequently invades the cranial base and orbit.
  • Esthesioneuroblastoma has a bimodal age distribution between 11 and 20 years and between 51 and 60 years.
  • Esthesioneuroblastoma accounts for approximately 1-5% of intranasal cancers.
  • The case is reported of a 79-year-old female patient with a Kadish stage C tumour with a one-year history of headache, nasal obstruction, anosmia, rhinorrhoea and epistaxis.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / radiotherapy. Paranasal Sinus Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2001 Sep;23(9):749-57 [11505485.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4A):2683-706 [9252701.001]
  • [Cites] Arq Neuropsiquiatr. 2002 Jun;60(2-A):303-7 [12068366.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):486-91 [12243826.001]
  • [Cites] Acta Otolaryngol. 2003 Apr;123(3):433-9 [12737303.001]
  • [Cites] Arch Otolaryngol. 1966 Dec;84(6):644-53 [5957143.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] Surg Clin North Am. 1977 Aug;57(4):751-62 [897964.001]
  • [Cites] Hum Pathol. 1983 Jun;14(6):538-50 [6303940.001]
  • [Cites] Arch Otolaryngol. 1983 Dec;109(12):797-802 [6639453.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Jan;14(1):11-22 [3335447.001]
  • [Cites] Laryngoscope. 1990 Nov;100(11):1199-201 [2233084.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):843-9 [1495347.001]
  • [Cites] Neurosurgery. 1993 May;32(5):706-14; discussion 714-5 [8492845.001]
  • [Cites] J Otolaryngol. 1997 Feb;26(1):1-7 [9055166.001]
  • [Cites] Strahlenther Onkol. 2002 Apr;178(4):187-91 [12040755.001]
  • (PMID = 18939712.001).
  • [ISSN] 0392-100X
  • [Journal-full-title] Acta otorhinolaryngologica Italica : organo ufficiale della Società italiana di otorinolaringologia e chirurgia cervico-facciale
  • [ISO-abbreviation] Acta Otorhinolaryngol Ital
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2644996
  •  go-up   go-down


80. Ward PD, Heth JA, Thompson BG, Marentette LJ: Esthesioneuroblastoma: Results and Outcomes of a Single Institution's Experience. Skull Base; 2009 Mar;19(2):133-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esthesioneuroblastoma: Results and Outcomes of a Single Institution's Experience.
  • OBJECTIVES: Analysis of outcomes of a cohort of patients with esthesioneuroblastoma.
  • SETTING: PATIENTS presenting with esthesioneuroblastoma from 1994 to 2006 in a tertiary care academic medical center.
  • PATIENTS: Fifteen consecutive patients diagnosed as having esthesioneuroblastoma were treated during this time period using a subcranial resection.
  • RESULTS: The overall survival was 100% and the overall disease-free survival was 49% and 24% at 5 and 15 years, respectively.
  • PATIENTS treated with radiation therapy following surgical resection had a 5- and 15-year disease-free survival of 83.3% compared with a 5- and 15-year disease-free survival of 26.7% and 0%, respectively, for patients whose initial treatment was surgery alone.
  • CONCLUSIONS: PATIENTS with esthesioneuroblastoma whose initial treatment consists of surgical resection followed by radiation therapy have a longer disease-free survival than patients treated with surgery alone.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Skull Base. 2007 Mar;17(2):119-23 [17768441.001]
  • [Cites] Head Neck. 2000 Sep;22(6):550-8 [10941155.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Feb;132(2):134-8 [16490869.001]
  • [Cites] Head Neck. 2005 Feb;27(2):138-49 [15654688.001]
  • [Cites] Acta Neurochir (Wien). 1997;139(9):857-68 [9351991.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4A):2683-706 [9252701.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1029-37 [9588547.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1023-7; discussion 1027-8 [9588546.001]
  • [Cites] Neurochirurgie. 1997;43(2):100-10 [9296053.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Nov 15;27(4):835-42 [8244813.001]
  • [Cites] Head Neck. 1993 May-Jun;15(3):190-6 [8491582.001]
  • [Cites] Neurosurgery. 1993 May;32(5):706-14; discussion 714-5 [8492845.001]
  • [Cites] J Otolaryngol. 1993 Jun;22(3):190-4 [8371330.001]
  • [Cites] Acta Neurochir (Wien). 1993;124(2-4):53-60 [8304071.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1993 Apr;119(4):385-93 [8457302.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):843-9 [1495347.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1991 Jul;117(7):779-82 [1863445.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1988 Oct;114(10):1114-22 [3415818.001]
  • [Cites] Cancer. 1989 Jun 15;63(12):2426-8 [2720589.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Sep;15(3):581-90 [3138210.001]
  • [Cites] Am J Surg Pathol. 1986 Oct;10(10):687-95 [2429566.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Mar;6(3):349-52 [7390908.001]
  • [Cites] Cancer. 1979 Sep;44(3):1087-94 [383268.001]
  • [Cites] Laryngoscope. 2003 Nov;113(11):1935-8 [14603051.001]
  • [Cites] Laryngoscope. 2003 Jan;113(1):155-60 [12514401.001]
  • [Cites] Lancet Oncol. 2001 Nov;2(11):683-90 [11902539.001]
  • [Cites] Head Neck. 2001 Sep;23(9):749-57 [11505485.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2001 Jun;127(6):687-90 [11405869.001]
  • [Cites] Laryngoscope. 2001 Mar;111(3):488-93 [11224781.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Mar;133(3):276-80 [17372086.001]
  • (PMID = 19721769.001).
  • [ISSN] 1531-5010
  • [Journal-full-title] Skull base : official journal of North American Skull Base Society ... [et al.]
  • [ISO-abbreviation] Skull Base
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2671304
  • [Keywords] NOTNLM ; Esthesioneuroblastoma / olefactory neuroblastoma / skull base tumor / subcranial
  •  go-up   go-down


81. Tselis N, Heyd R, Baghi M, Zamboglou N: Interstitial high-dose-rate-brachytherapy in advanced esthesioneuroblastoma. Laryngoscope; 2008 Nov;118(11):2006-10
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interstitial high-dose-rate-brachytherapy in advanced esthesioneuroblastoma.
  • Esthesioneuroblastoma is a rare neuroectodermal tumor of the nasal vault with an aggressive biological behavior that is characterized by local recurrence, atypical distant metastasis, and poor long-term prognosis.
  • We report two cases of primary metastatic and locally recurrent disease, which were treated with computed tomography-guided interstitial high-dose-rate brachytherapy in palliative and curative intent, respectively.
  • Computed tomography-guided interstitial high-dose-rate brachytherapy should be considered as a feasible treatment option for advanced esthesioneuroblastoma.
  • [MeSH-major] Brachytherapy / methods. Esthesioneuroblastoma, Olfactory / radiotherapy. Nasal Cavity. Nose Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18641524.001).
  • [ISSN] 1531-4995
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


82. García-Santana SM, Rodríguez JA, Serrano L, Hedges TR 3rd: Esthesioneuroblastoma presenting with complete external ophthalmoplegia. Semin Ophthalmol; 2009 Nov-Dec;24(6):245-6
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esthesioneuroblastoma presenting with complete external ophthalmoplegia.
  • Neuroimaging revealed a mass involving the medial wall of the left cavernous sinus, without orbital involvement.
  • Biopsy of the mass provided a pathologic diagnosis of esthesioneuroblastoma.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / pathology. Nasal Cavity / pathology. Nose Neoplasms / pathology. Ophthalmoplegia / pathology

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954376.001).
  • [ISSN] 1744-5205
  • [Journal-full-title] Seminars in ophthalmology
  • [ISO-abbreviation] Semin Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


83. Magee B, Samuelian J, Haines K, Chappel M, Penn I, Chin D, Anders D, Hinz J: Screening-level population risk assessment of nasal tumors in the US due to naphthalene exposure. Regul Toxicol Pharmacol; 2010 Jul-Aug;57(2-3):168-80
Hazardous Substances Data Bank. NAPHTHALENE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening-level population risk assessment of nasal tumors in the US due to naphthalene exposure.
  • Several naphthalene Unit Risk Factors (URFs) were proposed by the US Environmental Protection Agency in 2004 using data on the development of olfactory epithelial neuroblastomas and nasal respiratory epithelial adenomas in rats, but these URFs may be inappropriate and unnecessarily conservative for estimating human cancer risks.
  • The purpose of the present exercise was to perform a screening-level population risk assessment of the US population to compare the observed number of naphthalene-induced nasal tumors in the US to the number that would be predicted if the URFs for naphthalene were as proposed.
  • Results indicate that the total predicted burden of naphthalene-induced nasal tumors per year in the US (65,905 rare nasal tumors, of which 29,121 are olfactory epithelial neuroblastomas) is much greater than the number of these tumors actually observed per year (910 total nasal tumors, of which 66 are olfactory neuroblastomas) over the period 1973-2006.
  • This suggests that using rat nasal tumor data to derive a naphthalene URF for humans should be re-evaluated.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / chemically induced. Inhalation Exposure / adverse effects. Naphthalenes / toxicity. Nasal Cavity. Nose Neoplasms / chemically induced

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20156512.001).
  • [ISSN] 1096-0295
  • [Journal-full-title] Regulatory toxicology and pharmacology : RTP
  • [ISO-abbreviation] Regul. Toxicol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Naphthalenes; 2166IN72UN / naphthalene
  •  go-up   go-down


84. Villano JL, Bressler L, Propp JM, Valyi-Nagy T, Martin IK, Dolecek TA, McCarthy BJ: Descriptive epidemiology of selected olfactory tumors. J Neurooncol; 2010 Oct;100(1):73-80
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Descriptive epidemiology of selected olfactory tumors.
  • Olfactory tumors, especially olfactory neuroblastomas (ON) and carcinomas with neuroendocrine differentiation (CND), are extremely rare, and little descriptive epidemiologic information is available.
  • The objective of this study was to more fully describe selected olfactory tumors using a large population-based cancer incidence database.
  • The Surveillance, Epidemiology and End Results (SEER) 9 registries limited-use data were reviewed from 1973 to 2006 for selected nasal cavity (C30.0) and accessory sinus (C31.0-31.9) tumors.
  • Survival rates were highest for ON (>70% alive at 5 years after diagnosis) and poorest for CND (44% alive at 5 years).
  • It is not feasible to conduct prospective trials in patients with these rare diseases, and the importance of registry data in learning about olfactory tumors is emphasized.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 2000 Oct;110(10 Pt 1):1617-22 [11037813.001]
  • [Cites] Head Neck. 2009 Jun;31(6):748-58 [19189340.001]
  • [Cites] Lancet Oncol. 2001 Nov;2(11):683-90 [11902539.001]
  • [Cites] Cancer. 2002 Jul 15;95(2):243-8 [12124822.001]
  • [Cites] Laryngoscope. 2002 Aug;112(8 Pt 1):1450-5 [12172261.001]
  • [Cites] Cancer. 2002 May 15;94(10):2623-34 [12173330.001]
  • [Cites] Semin Cancer Biol. 2002 Dec;12(6):421-9 [12450728.001]
  • [Cites] Head Neck. 2004 May;26(5):435-41 [15122660.001]
  • [Cites] Cancer. 1982 Dec 1;50(11):2388-405 [7139532.001]
  • [Cites] Cancer Res. 1988 Jun 1;48(11):3282-7 [3365707.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2567-73 [15517582.001]
  • [Cites] Head Neck. 2005 Feb;27(2):138-49 [15654688.001]
  • [Cites] Adv Anat Pathol. 2005 May;12(3):134-43 [15900114.001]
  • [Cites] Am J Clin Pathol. 2005 Dec;124 Suppl:S110-21 [16468421.001]
  • [Cites] Otolaryngol Head Neck Surg. 2006 Sep;135(3):451-7 [16949981.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Mar;133(3):276-80 [17372086.001]
  • [Cites] Cancer Treat Rev. 2007 Nov;33(7):631-45 [17329031.001]
  • [Cites] Otolaryngol Head Neck Surg. 2008 Apr;138(4):452-8 [18359353.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):343-50 [18374508.001]
  • [Cites] J Neurooncol. 2008 Nov;90(2):201-4 [18633576.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3012-29 [11753979.001]
  • (PMID = 20151173.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / HHSN261200800766P; United States / PHS HHS / / HHSN26100800766P
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS475576; NLM/ PMC4070851
  •  go-up   go-down


85. Sharma S, Lasheen W, Walsh D: Paraneoplastic refractory hypercalcemia due to advanced metastatic esthesioneuroblastoma. Rhinology; 2008 Jun;46(2):153-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paraneoplastic refractory hypercalcemia due to advanced metastatic esthesioneuroblastoma.
  • Esthesioneuroblastoma (ENB) is a rare malignant neoplasm arising from the olfactory neuroepithelium.
  • ENB has no distinctive clinical picture, but often presents as chronic unilateral nasal obstruction or epistaxis.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / secondary. Hypercalcemia / etiology. Nasal Cavity. Nose Neoplasms / pathology. Paraneoplastic Syndromes / etiology

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18575019.001).
  • [ISSN] 0300-0729
  • [Journal-full-title] Rhinology
  • [ISO-abbreviation] Rhinology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


86. Murakami M, Kakita K, Kimura S, Hosokawa Y: Subdural extension of recurrent olfactory neuroblastoma. Case report. Neurol Med Chir (Tokyo); 2005 Nov;45(11):596-9
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subdural extension of recurrent olfactory neuroblastoma. Case report.
  • A 37-year-old man presented with olfactory neuroblastoma, which apparently recurred as diffuse extension in the subdural space of the cranial vault and spinal column 3 years after initial resection.
  • Histological examination of a biopsy specimen suggested recurrence of the olfactory neuroblastoma.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / pathology. Nasal Cavity / pathology. Neoplasm Recurrence, Local / pathology. Nose Neoplasms / pathology. Subdural Space / pathology

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16308521.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


87. Bist SS, Kumar R, Saxena RK, Gupta C: Esthesioneuroblastoma: A case report and review of the literature. Indian J Otolaryngol Head Neck Surg; 2006 Jul;58(3):294-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esthesioneuroblastoma: A case report and review of the literature.
  • Esthesioneuroblastoma (ENB) is an extremely rare malignant neoplasm of the nasal cavity.
  • We report the case of a middle aged man who presented with a 6-months history of progressive nasal obstruction, watering of the eye, headache and occasional epistaxis.
  • A diagnosis of esthesioneuroblastoma was established by histopathology and confirmed by immunohistochemistry.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):843-9 [1495347.001]
  • [Cites] Laryngoscope. 1990 Nov;100(11):1199-201 [2233084.001]
  • [Cites] Neurosurgery. 1993 May;32(5):706-14; discussion 714-5 [8492845.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4A):2683-706 [9252701.001]
  • [Cites] Laryngoscope. 2003 Mar;113(3):502-7 [12616204.001]
  • [Cites] Laryngoscope. 2000 Apr;110(4):635-40 [10764010.001]
  • [Cites] Laryngoscope. 2001 Jan;111(1):48-51 [11192899.001]
  • [Cites] Am J Rhinol. 2001 Jul-Aug;15(4):271-9 [11554661.001]
  • [Cites] Acta Otolaryngol. 2002 Mar;122(2):215-21 [11936917.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1023-7; discussion 1027-8 [9588546.001]
  • (PMID = 23120321.001).
  • [ISSN] 2231-3796
  • [Journal-full-title] Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
  • [ISO-abbreviation] Indian J Otolaryngol Head Neck Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3450429
  • [Keywords] NOTNLM ; Esthesioneuroblastoma / immunohistochemistry
  •  go-up   go-down


88. Holland H, Koschny R, Krupp W, Meixensberger J, Bauer M, Kirsten H, Ahnert P: Comprehensive cytogenetic characterization of an esthesioneuroblastoma. Cancer Genet Cytogenet; 2007 Mar;173(2):89-96
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comprehensive cytogenetic characterization of an esthesioneuroblastoma.
  • Esthesioneuroblastoma is a malignant neuroectodermal tumor originating from olfactory epithelial cells in the nasal vault.
  • Therefore, we performed comprehensive cytogenetic analyses of an esthesioneuroblastoma, Hyam's grade III-IV, using trypsin-Giemsa staining (GTG banding), multicolor fluorescence in situ hybridization (M-FISH), and locus-specific FISH complemented by molecular karyotyping using high-density single nucleotide polymorphism arrays.
  • Interestingly, we found two novel, so far not described deletions, del(2)(q37) and del(21)(q22).
  • Applying SNP array karyotyping, we confirmed the chromosomal aberrations del(2)(q37.3), del(3)(q27.2), del(10)(q26.11), chromosomal imbalance on 17q, del(21)(q22), and revealed a number of so far unknown aberrations (gain of 2q14.3, 13q33.3, and 13q34).
  • While the cytogenetically revealed low frequency mosaic del(6)(q22q24) was not visible using SNP array karyotyping, some of the smaller imbalances (SNP array data) could not have been detected by classic cytogenetic analysis.
  • [MeSH-major] Cytogenetic Analysis. Esthesioneuroblastoma, Olfactory / genetics. Nasal Cavity / metabolism. Nose Neoplasms / genetics

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17321323.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Almubaslat M, Africk C: Cerebral vasospasm after resection of an esthesioneuroblastoma: case report and literature review. Surg Neurol; 2007 Sep;68(3):322-8; discussion 328
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cerebral vasospasm after resection of an esthesioneuroblastoma: case report and literature review.
  • We illustrate in this report a case of cerebral vasospasm after resection of an esthesioneuroblastoma in an adult patient.
  • This is the first report of vasospasm after resection of this neoplasm.
  • Radiological studies revealed a large frontal lobe mass extending through the cribriform plate into the ethmoid sinus with accompanying brain edema.
  • The patient underwent a craniotomy for resection of the neoplasm.
  • Pathological findings were consistent with a high-grade esthesioneuroblastoma.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / surgery. Nasal Cavity. Nose Neoplasms / surgery. Postoperative Complications. Vasospasm, Intracranial / etiology

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17586013.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 35
  •  go-up   go-down


90. Chen YF, Yang AK, Zhang Q, Ouyang D, Chen WK, Chen FJ: [Clinical analysis of 53 cases of esthesioneuroblastoma]. Ai Zheng; 2009 Mar;28(3):308-11
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 53 cases of esthesioneuroblastoma].
  • BACKGROUND AND OBJECTIVE: The prognosis of esthesioneuroblastoma (ENB) patients is poor.
  • CONCLUSIONS: ENB is a malignant tumor with high rates of locoregional recurrence and distant metastasis.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / surgery. Nasal Cavity. Nose Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Combined Modality Therapy. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy, High-Energy. Retrospective Studies. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19619448.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


91. Li JS, Xie FY, Peng M, Han F: [Clinical analysis of 20 adults esthesioneuroblastoma with combined therapy]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Jan;44(1):36-9
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 20 adults esthesioneuroblastoma with combined therapy].
  • OBJECTIVE: To retrospectively compare the survival difference of 20 patients with esthesioneuroblastoma (EN) who received combined therapy, and try to analyze the most optimized modalities.
  • The disease free survival and overall survival rate were calculated by Kaplan-Meier method and compared by Log-rank method.
  • RESULTS: Follow up from beginning of treatment to 31th March, 2008, the 3-year overall survival rate was 50.0%, the 3-year disease free survival and overall survival rates were 16.7%, 25.0% for chemoradiation group and 75.0%, 87.5% for surgery plus radiotherapy group, respectively.
  • The disease free survival and overall survival rate of the latter group were better than the former (chi2 values were 6.81 and 7.33, P values were 0.0091 and 0.0068, respectively).
  • CONCLUSIONS: Surgery combined with adjuvant radiotherapy may increase the survival rate compared with induction chemotherapy followed by radiotherapy for local advanced esthesioneuroblastoma.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / therapy. Nasal Cavity. Nose Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Olfactory Nerve. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19484986.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


92. Kane AJ, Sughrue ME, Rutkowski MJ, Aranda D, Mills SA, Buencamino R, Fang S, Barani IJ, Parsa AT: Posttreatment prognosis of patients with esthesioneuroblastoma. J Neurosurg; 2010 Aug;113(2):340-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Posttreatment prognosis of patients with esthesioneuroblastoma.
  • OBJECT: There is no Class I evidence to guide the appropriate management of esthesioneuroblastoma (EN).
  • [MeSH-major] Esthesioneuroblastoma, Olfactory. Nasal Cavity. Nose Neoplasms

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2012 Dec;117(6):1206-7 [23020767.001]
  • (PMID = 20345216.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.; Review
  • [Publication-country] United States
  • [Number-of-references] 222
  •  go-up   go-down


93. Devaiah AK, Andreoli MT: Treatment of esthesioneuroblastoma: a 16-year meta-analysis of 361 patients. Laryngoscope; 2009 Jul;119(7):1412-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of esthesioneuroblastoma: a 16-year meta-analysis of 361 patients.
  • OBJECTIVES/HYPOTHESIS: This study reviews the published outcomes related to surgical (open, endoscopic, and endoscopic-assisted) and nonsurgical treatment for esthesioneuroblastoma.
  • METHODS: A meta-analysis of individual patient data for esthesioneuroblastoma publications between 1992 (the earliest identified description of endoscopic resection) and 2008 was conducted.
  • A total of 49 journal articles, comprising 1,170 cases of esthesioneuroblastoma, were included in the study.
  • [MeSH-major] Endoscopy. Esthesioneuroblastoma, Olfactory / surgery. Nasal Cavity. Nose Neoplasms / surgery
  • [MeSH-minor] Humans. Neoplasm Staging. Statistics, Nonparametric. Survival Analysis


94. Sharma S, Sharma MC, Johnson MH, Lou M, Thakar A, Sarkar C: Esthesioneuroblastoma - a clinicopathologic study and role of DNA topoisomerase alpha. Pathol Oncol Res; 2007;13(2):123-9
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esthesioneuroblastoma - a clinicopathologic study and role of DNA topoisomerase alpha.
  • Esthesioneuroblastoma (ENB) differs from adrenal neuroblastomas in its histopathologic and biologic characteristics.
  • The mass primarily involved the nose in 12 (63%) and paranasal sinuses in 7 cases (37%).
  • The difference in DNA topoisomerase alpha labeling index between the low- and highgrade ENB (medians: 10.4 and 22.3, respectively) was not statistically significant (p=0.0714), but it was suggestive of a positive association.
  • This preliminary study suggests the need to combine a simplified histologic grading with accurate staging in a reasonable attempt to assess local progression in esthesioneuroblastoma.
  • [MeSH-major] Antigens, Neoplasm / physiology. DNA Topoisomerases, Type II / physiology. DNA-Binding Proteins / physiology. Esthesioneuroblastoma, Olfactory / enzymology. Nasal Cavity / enzymology. Nose Neoplasms / enzymology
  • [MeSH-minor] Adolescent. Adult. Cell Proliferation. Female. Gene Expression Regulation, Enzymologic. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1999 Oct;109(10):1539-43 [10522919.001]
  • [Cites] Neurosurgery. 1993 May;32(5):706-14; discussion 714-5 [8492845.001]
  • [Cites] Laryngoscope. 2000 Aug;110(8):1262-5 [10942123.001]
  • [Cites] Cancer. 1994 May 15;73(10):2556-62 [8174053.001]
  • [Cites] J Neurooncol. 2002 Sep;59(3):217-26 [12241118.001]
  • [Cites] Cancer. 2004 Sep 15;101(6):1437-44 [15368332.001]
  • [Cites] Zhonghua Er Bi Yan Hou Ke Za Zhi. 2004 Jun;39(6):328-32 [15469075.001]
  • [Cites] Med Electron Microsc. 2002 Sep;35(3):160-6 [12353137.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Mar;133(3):276-80 [17372086.001]
  • [Cites] Lancet Oncol. 2001 Nov;2(11):683-90 [11902539.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2567-73 [15517582.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4A):2683-706 [9252701.001]
  • [Cites] Acta Oncol. 2004;43(1):35-42 [15068318.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 May;130(5):567-74 [15138422.001]
  • [Cites] Neurosurgery. 1998 May;42(5):1023-7; discussion 1027-8 [9588546.001]
  • [Cites] Histopathology. 2003 Apr;42(4):395-402 [12653952.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Feb;132(2):134-8 [16490869.001]
  • [Cites] Onkologie. 2003 Jun;26(3):261-7 [12845211.001]
  • [Cites] Neurosurgery. 1990 Nov;27(5):813-9; discussion 819-20 [2259415.001]
  • [Cites] Acta Oncol. 2000;39(2):231-5 [10859017.001]
  • [Cites] J Laryngol Otol. 1998 Jul;112(7):628-33 [9775291.001]
  • [Cites] Acta Oncol. 1993;32(4):399-402 [8369126.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] Br J Cancer. 1999 Oct;81(4):586-91 [10574242.001]
  • [Cites] Am J Clin Pathol. 2003 May;119(5):715-22 [12760291.001]
  • [Cites] Arq Neuropsiquiatr. 1995 Sep;53(3-B):577-86 [8585813.001]
  • [Cites] APMIS. 2002 Sep;110(9):639-45 [12529017.001]
  • [Cites] Laryngoscope. 1992 Aug;102(8):843-9 [1495347.001]
  • [Cites] Brain Pathol. 2004 Apr;14(2):158-63 [15193028.001]
  • [Cites] Am J Surg Pathol. 1998 Apr;22(4):391-8 [9580174.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1186-92 [14623748.001]
  • (PMID = 17607373.001).
  • [ISSN] 1219-4956
  • [Journal-full-title] Pathology oncology research : POR
  • [ISO-abbreviation] Pathol. Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


95. Doi M, Sugiyama T, Izumiyama H, Yoshimoto T, Hirata Y: Clinical features and management of ectopic ACTH syndrome at a single institute in Japan. Endocr J; 2010;57(12):1061-9
Hazardous Substances Data Bank. Corticotropin .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ectopic ACTH syndrome (EAS) is a diagnostic challenge because it is often indistinguishable from Cushing's disease.
  • Six cases deceased, including small cell carcinoma (2) and adenocarcinoma (1) of lung, neuroendocrine carcinoma of pancreas (1) and stomach (1), and olfactory neuroblastoma (1), whereas 4 cases survived after removal of the tumors, including bronchial carcinoid tumor (3) and thymic hyperplasia (1).
  • [MeSH-major] ACTH Syndrome, Ectopic / diagnosis
  • [MeSH-minor] Adrenocorticotropic Hormone / blood. Adult. Aged. Corticotropin-Releasing Hormone. Dexamethasone. Diabetes Mellitus. Diagnosis, Differential. Female. Glucose Intolerance. Humans. Hydrocortisone / blood. Hyperlipidemias. Hypertension. Hypokalemia. Japan. Male. Metyrapone / therapeutic use. Middle Aged. Neoplasms / diagnosis. Neoplasms / secretion. Neoplasms / surgery. Pituitary ACTH Hypersecretion. Skin Pigmentation. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. METYRAPONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21076235.001).
  • [ISSN] 1348-4540
  • [Journal-full-title] Endocrine journal
  • [ISO-abbreviation] Endocr. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone; 9002-60-2 / Adrenocorticotropic Hormone; 9015-71-8 / Corticotropin-Releasing Hormone; WI4X0X7BPJ / Hydrocortisone; ZS9KD92H6V / Metyrapone
  •  go-up   go-down


96. Sharma NK, Pandey J, Gupta N, Jain RK: Growth and physiological response of Arthrobacter protophormiae RKJ100 toward higher concentrations of o-nitrobenzoate and p-hydroxybenzoate. FEMS Microbiol Lett; 2007 Jun;271(1):65-70
Hazardous Substances Data Bank. 4-HYDROXYBENZOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the present study we have characterized the growth response and physiological changes (adaptations) of a Gram-positive bacterium, Arthrobacter protophormiae RKJ100, toward the higher concentrations of two aromatic compounds, viz. o-nitrobenzoate (ONB) and p-hydroxybenzoate (PHB).
  • Arthrobacter protophormiae RKJ100 could utilize 30 mM ONB and 50 mM PHB as sole sources of carbon and energy.
  • It was capable of growth on higher concentrations of ONB (up to 200 mM) and PHB (up to 150 mM) when the cells were pre-exposed to lower concentrations of these compounds.
  • In addition, Bacterial Adhesion To Hydrocarbon (BATH) assay and scanning electron microscopy showed substantial increase in cell surface hydrophobicity and decrease in cell size of A. protophormiae RKJ100 when grown on ONB and PHB as compared to succinate-grown cells.

  • Hazardous Substances Data Bank. SUCCINIC ACID .
  • Hazardous Substances Data Bank. CARBON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17391368.001).
  • [ISSN] 0378-1097
  • [Journal-full-title] FEMS microbiology letters
  • [ISO-abbreviation] FEMS Microbiol. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 2-nitrobenzoate; 0 / Fatty Acids; 0 / Nitrobenzoates; 0 / Parabens; 7440-44-0 / Carbon; AB6MNQ6J6L / Succinic Acid; JG8Z55Y12H / 4-hydroxybenzoic acid
  •  go-up   go-down


97. Kodama S, Kawano T, Suzuki M: Endoscopic transnasal resection of ectopic esthesioneuroblastoma in the pterygopalatine fossa: technical case report. Neurosurgery; 2009 Dec;65(6 Suppl):E112-3; discussion E113
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic transnasal resection of ectopic esthesioneuroblastoma in the pterygopalatine fossa: technical case report.
  • OBJECTIVE: Esthesioneuroblastoma is a rare, malignant neoplasm arising from the olfactory neuroepithelium in the upper nasal cavity.
  • Even more rare is ectopic esthesioneuroblastoma developing from the region outside the olfactory epithelium.
  • In addition, tumors occurring in the pterygopalatine fossa (PPF) are uncommon, and the endoscopic transnasal approach for the resection of malignant tumors in this region is also uncommon.
  • CLINICAL PRESENTATION: We describe an esthesioneuroblastoma arising from the left maxillary sinus and PPF.
  • TECHNIQUE: The endoscopic transnasal approach could be successfully used for the complete removal of malignant tumors in the PPF.
  • The endoscopic transnasal approach might become the treatment of choice for malignant tumors in the PPF.
  • [MeSH-major] Choristoma / surgery. Endoscopy / methods. Esthesioneuroblastoma, Olfactory / surgery. Nasal Cavity / surgery. Nose Neoplasms / surgery. Pterygopalatine Fossa / surgery
  • [MeSH-minor] Female. Humans. Maxillary Sinus / pathology. Maxillary Sinus / physiopathology. Maxillary Sinus / surgery. Maxillary Sinus Neoplasms / pathology. Maxillary Sinus Neoplasms / radiotherapy. Maxillary Sinus Neoplasms / surgery. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / physiopathology. Neoplasm Recurrence, Local / surgery. Neurosurgical Procedures / instrumentation. Neurosurgical Procedures / methods. Otorhinolaryngologic Surgical Procedures / instrumentation. Otorhinolaryngologic Surgical Procedures / methods. Postoperative Complications / etiology. Postoperative Complications / physiopathology. Postoperative Complications / prevention & control. Radiotherapy. Skull / anatomy & histology. Skull / surgery. Sphenoid Bone / anatomy & histology. Sphenoid Bone / surgery. Treatment Outcome

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19935009.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


98. Yu T, Xu YK, Li L, Jia FG, Duan G, Wu YK, Li HY, Yang RM, Feng J, Ye XH, Qiu YW: Esthesioneuroblastoma methods of intracranial extension: CT and MR imaging findings. Neuroradiology; 2009 Dec;51(12):841-50
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esthesioneuroblastoma methods of intracranial extension: CT and MR imaging findings.
  • INTRODUCTION: Esthesioneuroblastoma (ENB) is an aggressive neuroectodermal malignancy in the upper nasal cavity with local infiltration and lymphatic or hematogenous metastasis.
  • The primary tumors were well-defined soft-tissue masses centered in the roof of the nasal cavity eroding into the paranasal sinuses (11/11), the contralateral nasal cavity (4/11), the cranial cavity (5/11), and the fossa orbitalis (3/11).
  • CONCLUSION: Three types of direct intracranial extensions by ENB can be found on CT and MRI: cranio-orbital-nasal-communicating ENB, cranio-nasal-communicating ENB, and orbital-nasal-communicating ENB.
  • [MeSH-major] Brain Neoplasms / diagnosis. Esthesioneuroblastoma, Olfactory / diagnosis. Magnetic Resonance Imaging / methods. Nasal Cavity / diagnostic imaging. Nasal Cavity / pathology. Nose Neoplasms / diagnosis. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Laryngoscope. 1999 Oct;109(10):1539-43 [10522919.001]
  • [Cites] Laryngoscope. 2003 Mar;113(3):502-7 [12616204.001]
  • [Cites] AJR Am J Roentgenol. 1979 Jul;133(1):140-1 [110050.001]
  • [Cites] Neurosurg Focus. 2002 May 15;12 (5):e4 [16119902.001]
  • [Cites] Am J Otolaryngol. 2007 May-Jun;28(3):196-200 [17499140.001]
  • [Cites] Skull Base. 2006 Feb;16(1):25-30 [16880898.001]
  • [Cites] Clin Nucl Med. 2006 Mar;31(3):172-4 [16495744.001]
  • [Cites] Laryngoscope. 2001 Mar;111(3):488-93 [11224781.001]
  • [Cites] J Neurooncol. 2008 Nov;90(2):201-4 [18633576.001]
  • [Cites] Am J Clin Pathol. 2008 Mar;129(3):367-76 [18285258.001]
  • [Cites] J Neurooncol. 2002 Sep;59(3):217-26 [12241118.001]
  • [Cites] Otolaryngol Head Neck Surg. 2008 Apr;138(4):452-8 [18359353.001]
  • [Cites] Cancer. 2004 Sep 15;101(6):1437-44 [15368332.001]
  • [Cites] J Comput Assist Tomogr. 1978 Sep;2(4):412-20 [701520.001]
  • [Cites] Head Neck. 2005 Feb;27(2):138-49 [15654688.001]
  • [Cites] Skull Base. 2008 Jan;18(1):73-6 [18592016.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2007 Mar;133(3):276-80 [17372086.001]
  • [Cites] Br J Neurosurg. 1998 Jun;12 (3):264-6 [11013692.001]
  • [Cites] Arq Neuropsiquiatr. 2002 Jun;60(2-A):303-7 [12068366.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1960 Aug;13:908-12 [14422003.001]
  • [Cites] Lancet Oncol. 2001 Nov;2(11):683-90 [11902539.001]
  • [Cites] Cancer. 2004 Dec 1;101(11):2567-73 [15517582.001]
  • [Cites] Anticancer Res. 1997 Jul-Aug;17(4A):2683-706 [9252701.001]
  • [Cites] Otolaryngol Head Neck Surg. 2004 May;130(5):567-74 [15138422.001]
  • [Cites] Laryngoscope. 2003 Dec;113(12):2086-90 [14660907.001]
  • [Cites] Endocr Pract. 2004 Mar-Apr;10(2):119-24 [15256328.001]
  • [Cites] Head Neck. 2000 Sep;22(6):550-8 [10941155.001]
  • [Cites] J Thorac Oncol. 2007 Jan;2(1):93-5 [17410019.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Aug;15(7):1259-62 [7976934.001]
  • [Cites] Acta Otolaryngol. 2003 Apr;123(3):433-9 [12737303.001]
  • [Cites] Acta Otolaryngol. 2002 Mar;122(2):215-21 [11936917.001]
  • [Cites] Neurosurg Clin N Am. 2000 Oct;11(4):693-701 [11082179.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2006 Feb;132(2):134-8 [16490869.001]
  • [Cites] Onkologie. 2003 Jun;26(3):261-7 [12845211.001]
  • [Cites] Acta Oncol. 2000;39(2):231-5 [10859017.001]
  • [Cites] Acta Neurochir (Wien). 2004 Sep;146(9):1043-5 [15340818.001]
  • [Cites] Clin Neuropathol. 2000 Mar-Apr;19(2):63-9 [10749286.001]
  • [Cites] Cancer. 1976 Mar;37(3):1571-6 [1260676.001]
  • [Cites] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2006 Apr;41(4):276-80 [16848177.001]
  • [Cites] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2005 May;40(5):363-5 [16229181.001]
  • [Cites] APMIS. 2002 Sep;110(9):639-45 [12529017.001]
  • [Cites] Pathol Int. 2001 Dec;51(12):942-7 [11844067.001]
  • [Cites] Curr Opin Otolaryngol Head Neck Surg. 2003 Apr;11(2):112-8 [14515089.001]
  • [Cites] J Neurooncol. 2004 Oct;70(1):73-5 [15527110.001]
  • [Cites] Zhonghua Zhong Liu Za Zhi. 1999 Mar;21(2):134-5 [11776856.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):634-44 [18207036.001]
  • [Cites] Rhinology. 2008 Jun;46(2):153-5 [18575019.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1969 Jan;105(1):7-13 [5774282.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 2003 Nov;129(11):1186-92 [14623748.001]
  • (PMID = 19669739.001).
  • [ISSN] 1432-1920
  • [Journal-full-title] Neuroradiology
  • [ISO-abbreviation] Neuroradiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


99. Bumm K, Grizzi F, Franceschini B, Koch M, Iro H, Wurm J, Ceva-Grimaldi G, Dimmler A, Cobos E, Dioguardi N, Sinha UK, Kast WM, Chiriva-Internati M: Sperm protein 17 expression defines 2 subsets of primary esthesioneuroblastoma. Hum Pathol; 2005 Dec;36(12):1289-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sperm protein 17 expression defines 2 subsets of primary esthesioneuroblastoma.
  • Esthesioneuroblastomas (ENBs) are rare malignant tumors of the nasal vault, the origin, diagnosis, and management of which are still subjects of discussion.
  • We here show that sperm protein 17 (Sp17) is expressed in the ciliated cells of the normal olfactory epithelium and in a proportion of primary ENB lesions.
  • We found an association between Sp17 expression and metastases at relapse (P = .035), chromogranin expression (P = .014), and a female sex prevalence.
  • [MeSH-major] Carrier Proteins / metabolism. Esthesioneuroblastoma, Olfactory / secondary. Nasal Cavity / pathology. Nose Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, Surface. Biomarkers, Tumor / metabolism. Child. Chromogranins / metabolism. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Olfactory Mucosa / metabolism. Olfactory Mucosa / pathology

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16311122.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Chromogranins; 0 / SPA17 protein, human
  •  go-up   go-down


100. Eich HT, Müller RP, Micke O, Kocher M, Berthold F, Hero B: Esthesioneuroblastoma in childhood and adolescence. Better prognosis with multimodal treatment? Strahlenther Onkol; 2005 Jun;181(6):378-84
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Esthesioneuroblastoma in childhood and adolescence. Better prognosis with multimodal treatment?
  • BACKGROUND AND PURPOSE: Only 3% of all malignant intranasal tumors are esthesioneuroblastomas (ENB) and only 20% of these rare neuroectodermal tumors are diagnosed up to 20 years of age.
  • To investigate the influence of radio- and chemotherapy, the treatment and course of the disease in children and adolescents with ENB were analyzed retrospectively.
  • Median age at diagnosis was 14.0 years (range, 5-20 years).
  • Complete resection (R0) was achieved in 15 out of 17 patients with surgery including all five patients with preoperative chemotherapy due to unresectable primary at diagnosis.
  • [MeSH-major] Esthesioneuroblastoma, Olfactory / radiotherapy. Nasal Cavity. Nose Neoplasms / radiotherapy
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Male. Neoplasm Staging. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - Esthesioneuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15925980.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down






Advertisement